|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
02/2013 | Recent | 13: Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions February patent applications/inventions, industry category 02/13Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 02/28/2013 > 163 patent applications in 101 patent subcategories. patent applications/inventions, industry category
20130052127 - Composite body for antigen or drug delivery: The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens... Agent: Kyusyu University, National University Corporation
20130052130 - Branched discreet peg constructs: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state,... Agent: Quanta Biodesign, Ltd.
20130052129 - Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty... Agent: The General Hospital Corporation
20130052128 - Upar binding agents and methods of use thereof: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.... Agent:
20130052131 - Nanoparticles, methods of making nanoparticles, and methods of use: Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like.... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130052132 - Method for producing radioactively labeled polypeptide: b
20130052133 - Se-72/as-72 generator system based on se extraction/ as reextraction: The preparation of a 72Se/72As radioisotope generator involves forming an acidic aqueous solution of an irradiated alkali bromide target such as a NaBr target, oxidizing soluble bromide in the solution to elemental bromine, removing the elemental bromine, evaporating the resulting solution to a residue, removing hydrogen chloride from the residue,... Agent: Los Alamos National Security, LLC
20130052135 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant... Agent: Medimmune, LLC
20130052134 - Peg-plga-pll polymer and method for preparing and using the same as the drug and gene carrier: This invention belongs to the nanotechnology field, and discloses a nano drug delivery system with polyethyleneglycol-poly(lactic-co-glycolic acid)-poly-L-lysine (PEG-PLGA-PLL) polymer as the skeleton. The carrier can have the function of passive targeting through control of the carrier particle size. The polymer skeleton is modified through introducing side chains and specific targeting... Agent: Shanghai Cancer Institute
20130052136 - Methods and apparatuses for predicting the effects of erythropoiesis stimulating agents, and for determining a dose to be administered: The present invention relates to a method for predicting the concentration or the mass of hemoglobin or an approximation thereof, respectively, in a body fluid and/or an extracorporeal sample thereof of a patient at a later, second point of time, the patient having theoretically or in reality been administered a... Agent: Fresenius Medical Care Deutschland Gmbh
20130052140 - Fe3o4/tio2 composite nano-particle, its preparation and application in magnetic resonance imaging contrast agents: This invention provides a Fe3O4/TiO2 composite nano-particle, its preparation and application in the magnetic resonance imaging (MRI) contrast agent, wherein the preparation of Fe3O4/TiO2 composite nano-particles has the followings steps: trivalent iron compounds and bivalent iron compounds are dissolved into a reducing acid water solution, and then added with tetravalent... Agent:
20130052141 - Hyperpolarized lactate contrast agent for determination of ldh activity: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H]lactate.... Agent: Ge Healthcare Limited
20130052142 - Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate... Agent: Celonova Biosciences Germany Gmbh
20130052143 - Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same: An liquid preparation for oral administration in digestive tract imaging, wherein: the preparation comprises an iodine compound, an electrolyte, and a water-soluble polymer; and the iodine content is 1.5 to 12.0 mg/mL.... Agent: Ajinomoto Co., Inc.
20130052138 - Methods and compositions for diagnostic and therapeutic targeting of cox-2: The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.... Agent: Vanderbilt University
20130052137 - Para amino benzoic acid based nanotubes: The invention relates to nanotubes and processes for making them and intermediates of a drug moiety or its derivative/s as a structural moiety with side chain/s capable of promoting self aggregation. The side chain/s are mono or a multiple of alkyl chain/s that are substituted or unsubstituted capable of creating... Agent: Indian Institute Of Chemical Technology
20130052139 - Method and kit for quantifying risk predictor: A method and a kit for quantification of at least one predictor promoting at least one multifactorial disease, intended for use in assessment of the risk for developing or progression of the at least one multifactorial disease for a subject are disclosed. The kit comprises a plurality of reservoir units... Agent:
20130052144 - Deodorant foams: A body deodorant which is easier to apply, has an improved feeling on the skin and which also leaves no wet feeling includes water, at least one water-soluble polyol selected from the group of polyols having 2-9 C-atoms and 2-6 hydroxyl groups and the polyether polyols having a molecular weight... Agent: Henkel Ag & Co. Kgaa
20130052145 - Adhesive slow-release formulations for the local administration of curcumin: Through the combined use of solvents with polyacrylic acid, it is possible to produce curcumin formulations that are stable in liquid form, while having both mucoadhesive and slow-release properties and ensure a solubility of the active ingredient of up to 15% (w/v).... Agent: Orphanidis Pharma Research Gmbh
20130052146 - Therapeutic dental composition and related methods: r
20130052147 - Compound applying to skin and a method making the same: A compound applying to skin and a method making the same comprises certain proportions for following first components: Dimethicone Crosspolymer, Dimethicone/Vinyl Dimethicone Crosspolymer, Cyclotetrasiloxane, Dimethicone, Cetyl PEG/PPG-15/15 Butyl Ether Dimethicone, Squalane, and Titanium Dioxide. Second components, third components, and fourth components with specific proportions as claimed are timely added in... Agent:
20130052148 - Personal care composition: The present invention relates to a personal care composition. More particularly the present invention relates to stabilization of UVA sunscreen dibenzoylmethane derivatives or even more particularly Parsol 1789™ (4-t-butyl-4′-methoxydibenzoyl-methane) in personal care compositions. It is an object of the present invention to provide a personal care composition with relatively long... Agent:
20130052149 - Process for treating and/or forming a non-newtonian fluid using microchannel process technology: The disclosed invention relates to a process, comprising: conducting unit operations in at least two process zones in a process microchannel to treat and/or form a non-Newtonian fluid, a different unit operation being conducted in each process zone; and applying an effective amount of shear stress to the non-Newtonian fluid... Agent: Velocys, Inc.
20130052150 - Method of reducing the odour of sulphur-bound products: Method of reducing the odour of sulphur-bound products, in particular modified sulphur or sulphur concrete, comprising contacting the sulphur-bound products with a bleaching agent, like e.g. sodium hydrochloride or hydrogen peroxide. The resulting sulphur-bound products emit reduced levels of sulphur-containing gases such as H2S and SO2 and have a reduced... Agent:
20130052151 - 3-methyl-6-cyclohexadecen-1-one and its use in perfume compositions: The present invention is directed to a novel compound, 3-methyl-cyclohexadec-6-enone, and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of 3-methyl-cyclohexadec-6-enone.... Agent:
20130052153 - Method of preparing hydrogel structure: A method of preparing hydrogel structure, wherein the hydrogel structure comprises: (a) a one way penetrating polyurethane film layer, (b) a hydrophobic pressure sensitive adhesive layer, (c) a multi-directional elastic meltblown nonwoven, (d) an interpenetrating polymer network, and (e) a hydrophilic hydrogel; and the method comprises: (i) coating the hydrogel... Agent: Compose Element Limited
20130052152 - Protective wound dressing device for oral and pharyngeal space: The present invention provides a wound dressing comprising a tessellated water-soluble molding matrix comprised of a polymer selected from the group consisting of polyvinyl alcohol, gelatin, and mixtures thereof and a 1,1-disubstituted ethylene monomer. The present invention further provides methods of using the wound dressing and kits containing the wound... Agent:
20130052154 - Compositions and methods for the treatment of lung inflammation: Compositions and methods for the treatment of inflammation are provided.... Agent: Board Of Regents Of The University Of Nebraska
20130052155 - Compositions and methods for treating a disorder or defect in soft tissue: The present invention encompasses methods and compositions for generating a biomimetic proteoglycan. The invention includes methods of treating a disease, disorder, or condition of soft tissue using a biomimetic proteoglycan.... Agent: Drexel University
20130052156 - Antiviral method: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and enhancers selected from cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.... Agent: Gojo Industries, Inc.
20130052160 - Compounds and uses thereof to induce an immunogenic cancer cell death in a subject: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the... Agent: Institut Gustave Roussy
20130052159 - Methods for treatment of microbial disorders: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.... Agent:
20130052158 - Use of autologous effector cells for treatment of multiple myeloma: The present disclosure provides methods for treating multiple myeloma using autologous expanded and activated NK cells.... Agent: University Of Arkansas For Medical Science
20130052157 - Use of il-17e for cancer treatment: The present invention provides methods, kits, and compositions for treating cancer with cytotoxic agents. Preferably, the cytotoxic agents are selected from: IL-25, BMP1O, FGF1 1, VDBP, ATIII and IL1-F7, and any combination thereof. In other preferred embodiments, the cancer is breast cancer. These agents can be supplied, for example, as... Agent: The Regents Of The University Of California
20130052161 - Inhibitors of flaviviridae viruses: e
20130052162 - Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon: The present invention demonstrates the important role of C/EBPε in innate immune response against pathogens. Specifically, the inventors showed that in the absence of functional C/EBPε, mice are severely impaired in their ability to clear S. aureus infection. Neutrophils are particularly affected, and susceptibility to S. aureus can be rectified... Agent: Cedars-sinai Medical Center
20130052163 - Human rhinovirus (hrv) antibodies: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease... Agent: Theraclone Sciences, Inc.
20130052164 - Isolated nucleotide molecule and method of sensing and killing of pathogenic microorganism: The present invention relates to an isolated nucleic acid molecule comprising a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a protein produced by said pathogenic microorganism; a second nucleotide sequence encoding an antimicrobial peptide, wherein... Agent: Nanyang Technological University
20130052170 - Grafting material for genetic and cell therapy: Disclosed is a method for producing a grafting material that comprises a step in which a grafting material that expresses a secreted protein is obtained by differentiating iPS cells that have had a gene for a secreted protein introduced therein.... Agent: Kyoto Prefectural Public University Corporation
20130052171 - Immunomodulatory isolated lactobacillus strainand application thereof: An immunomodulatory isolated Lactobacillus strain is disclosed. The isolated Lactobacillus strain (accession No. CCTCC M 2011279) is purified from plant fermentation products. The isolated Lactobacillus strain, whatever itself or the composition including the same, can specifically enhance the amount of nitric oxide (NO), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6),... Agent: Chia Nan University Of Pharmacy And Science
20130052172 - Methods for diagnosing and treating cardiac defects: The present disclosure defines a method for identifying and/or treating risk and/or occurrence of cardiac defect. As is shown herein, microbiomes are reproducibly and detectably associated with cardiac defect risk factors and changes to the microbiome can directly alter cardiac defect risk. The present disclosure demonstrates that microbial signatures can... Agent:
20130052173 - Use of menadione and derivatives thereof for treating biomasses: A method for limiting the growth of microorganisms in a biomass that can he used for, or is the result of, the production of biofuels by treating said biomass with a compound selected from the group constituted by menadione, menadione derivatives and mixtures thereof.... Agent:
20130052165 - Methods of producing adenovirus vectors and viral preparations generated thereby: The present invention, in some embodiments thereof, relates to methods of producing adenoviruses such as pro- and anti-angiogenic adenovirus vectors and preparations generated thereby. Particularly, in some embodiments, the viral vectors comprise a heterologous pro- or anti-angiogenic gene under the transcriptional control of the murine pre-proendothelin promoter (e.g. PPE-1-3X), for... Agent:
20130052166 - Materials and methods for minimally-invasive administration of a cell-containing flowable composition: The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery... Agent: Pervasis Therapeutics, Inc.
20130052167 - Methods and apparatus for creating particle derivatives of hdl with reduced lipid content: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to... Agent: Hdl Therapeutics
20130052168 - Methods and compositions for tissue regeneration: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF,... Agent: Healthpoint International, LLC
20130052169 - Stem cell bank for personalized medicine: A stem cell bank is disclosed which stores stem cells collected from individuals throughout their entire life. The stem cell bank stores stem cells of various types, which are obtained from a plurality of sources from a single individual. Also provided are methods of personalized medicine that utilizes cells stored... Agent: Stem Cell Medicine Ltd.
20130052174 - Cell populations having immunoregulatory activity, methods for the preparation and uses thereof: There is provided inter alia a method for the preparation and/or generation of immunomodulatory cells which comprises contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for between about 2 hours and about 25 days.... Agent:
20130052175 - Oil suspension-based molded food products: A molded food product is provided that has a high fat and protein content and a low carbohydrate content. The food product is suitable for human or animal consumption. The food product can serve as a snack or as a carrier for active ingredients such as vitamins, minerals, herbs and... Agent: Biopet Ltd.
20130052176 - Aptamer for ngf and use thereof: m
20130052178 - Cholesterol ester for reducing cholesterol absorption: The present invention relates to a method for reducing cholesterol absorption in an animal comprising administering to the animal a composition comprising an effective amount of at least one cholesterol ester.... Agent: Dupont Nutrition Biosciences Aps
20130052177 - Monomeric forms of human aminoacyl-t-rna synthetases having non-canonical biological activities: Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.... Agent: The Scripps Research Institute
20130052179 - Arginine deiminase mutant and preparation and application thereof: The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino... Agent:
20130052181 - Combined use of ribonuclease and artemisinin: The invention discloses a kit which comprises a formulation containing artemisinin or the derivatives thereof, a formulation containing ribonuclease, and a specification.... Agent: Shanghai Biomodel Organism Science & Technology Development Co., Ltd.
20130052180 - Method for producing lipase, transformed yarrowia lipolytica cell capable of producing said lipase and their uses: Method for producing Yarrowia lipolytica acid-resistant recombinant lipase utilizing a culture medium without any products of animal origin or non-characterized mixtures such as tryptone, peptone or lactoserum, in addition to its uses. Recombinant strain of Yarrow lipolytica producing an excessive amount of lipase Lip2 referred to as YL-LIP2-6C and filed... Agent: Laboratoires Mayoly Spindler
20130052182 - Method of reducing biofilms: The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as... Agent: Lysando Ag
20130052183 - Methods for the treatment of morgellons disease: Provided herein are compositions and methods of using such compositions to treat Morgellons and other symptoms associated with skin and nail diseases and disorders.... Agent: Gordon Stamp. R.n.
20130052184 - Gelatinase inhibitors and prodrugs: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing... Agent: University Of Notre Dame Du Lac
20130052185 - Yeast hydrolysate having obesity treatment effects and antioxidant activity: The present invention relates to a yeast hydrolysate, which inhibits the deposition of fat around internal organs so as to treat or prevent obesity, and which has antioxidant activity. In addition, the present invention relates to a method for preparing the yeast hydrolysate, and to a food, animal food, pharmaceutical... Agent: Neo Cremar Co., Ltd.
20130052187 - Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions: New conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well... Agent: Biomerieux Sa
20130052189 - Method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which... Agent:
20130052186 - Plasma carboxypeptidase b as a predictor for disease severity and response: Compositions and methods are provided for prognostic classification of individuals into groups that are informative of the individual's likelihood of developing severe disease associated with undesirable complement activation. Individuals having one or both alleles for a more stable or active carboxypeptidase B variant have a reduced propensity for developing severe... Agent:
20130052188 - Systems and methods for obtaining immunoglobulin from blood: The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component... Agent: Baxter International Inc.
20130052191 - Anti-alpha2 integrin antibodies and their uses: The invention relates to antibodies directed to α2β1 integrin and their uses, including humanized anti-alpha 2 (α2) integrin antibodies and methods of treatment with anti-α2integrin antibodies. More specifically the present invention relates to humanized anti-α2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human... Agent: Sanofi
20130052190 - Crth2 antagonists for treatment of eosinophilic diseases and conditions: The present invention provides a method for the treatment of allergic and inflammatory diseases or conditions by administering a compound of Formula (I). The invention provides a method of treatment that is particularly suited for patients with a high degree of airway eosinophilia in contrast to those with a lower... Agent: Oxagen Limited
20130052192 - Activatable constructs: The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and... Agent: Novo Nordisk A/s
20130052193 - Controlling allergy and asthma by activating human dcs via dectin-1 or toll-like receptor 2 (tlr2): The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused... Agent: Baylor Research Institute
20130052194 - Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same: Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same.... Agent: The Trustees Of The University Of Pennsylvania
20130052195 - Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof: The present disclosure relates to compositions and methods for treating autoimmune diseases including rheumatoid arthritis. In particular, the present disclosure relates to compositions comprising IL-6 antagonists (e.g., anti-IL6 or anti-IL6R or anti-hyperIL6) and TNF-α antagonists (e.g., (anti-TNF or etanercept) and methods of using same in the treatment of rheumatoid arthritis.... Agent: Emergent Product Development Seattle,llc
20130052196 - Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to induce an immunostimulatory effect in a T cell when such a T cell is contacted with an antigen presenting cell (APC) that has been previously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are... Agent: Tolerx, Inc.
20130052198 - Anti-inflammatory factors: The present invention provides particular anti-inflammatory factors, compositions containing them, methods of making, identifying, and/or characterizing them, and methods of using them. In some embodiments, provided factors are expressed by human bone marrow stromal cells (MSC). In some embodiments, provided factors are characterized by an ability, when contacted with mammalian... Agent: Massachusetts Institute Of Technology
20130052197 - Novel anti-cd98 antibody and use thereof: The invention provides a therapeutic agent for autoimmune diseases, particularly type 1 diabetes and rheumatoid arthritis, as well as a method of preparing the therapeutic agent and a method of treating an autoimmune disease with the therapeutic agent. The therapeutic agent is an anti-CD98 antibody that does not inhibit amino... Agent: The University Of Tokushima
20130052201 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Amgen, Inc.
20130052199 - Molecular determinants of myeloma bone disease and uses thereof: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods to control bone loss, treat bone disease and prevent tumor growth in bones of individual.... Agent: Board Of Trustees Of The University Of Arkansas
20130052200 - Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein: The present invention refers to human antibodies which are directed against α-Synuclein (α-Syn) and their use in medicine and diagnosis.... Agent: Dr. Rentschler Holding Gmbh & Co. Kg
20130052202 - High affinity, anti-human ige antibodies: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These... Agent:
20130052203 - In vivo screening models for treatment of qc-related disorders: A double transgenic non-human animal, in particular a transgenic mouse encoding Qpct proteins, which have been implicated in Qpct-related diseases, and Amyloid Precursor Protein (APP). Also provided are cells and cell lines comprising transgenes encoding for Qpct and APP. Also provided are methods and compositions for evaluating agents that affect... Agent: Probiodrug Ag
20130052204 - (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine: Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen.... Agent:
20130052205 - Flt3 receptor antagonists for the treatment or the prevention of pain disorders: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.... Agent:
20130052206 - Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients: The invention provides methods and compositions for early diagnosis and treatment of a disease associated with a specific antibody by employing the detection of a cross-idiotypic epitope on the specific antibody to detect the cells that produce the antibody before the development of clinical symptoms of the disease.... Agent: Vincent Agnello
20130052207 - Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma: A method of detecting a poor-prognosis stage I lung adenocarcinoma in a mammal, comprising a step of measuring the copy number of ACTN4 gene in the cells of the stage I lung adenocarcinoma tissue obtained from the mammal, wherein, when the copy number of the gene exceeds 4, the stage... Agent: Japan Health Sciences Foundation
20130052208 - Process for preparing an immunoglobulin composition: A process is provided for the preparation of an immunoglobulin composition from a plasma fraction having immunoglobulins, and antibody preparations prepared utilizing the process.... Agent: Biotest Ag
20130052209 - Protein drug formulations and packages: Compositions and methods that include stabilized protein drugs are described. In addition, protein drug formulations that are more stable under ambient conditions are described. The formulations include one or more polyamino acid ligands of the protein drug.... Agent: Purdue Research Foundation
20130052210 - Use of ccl1 in therapy: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.... Agent: Rappaport Family Institute For Research In The Medical Sciences
20130052212 - Method for allogeneic cell therapy: A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft... Agent: Immunovative Therapies, Ltd.
20130052211 - Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof: Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration... Agent: South Alabama Medical Science
20130052214 - Identification of a peptide(s) that induces autoimmune anterior uveitis: The present invention provides an immunogenic composition effective for inducing, treating, reducing the incidence of or severity of clinical signs associated with autoimmune anterior uveitis.... Agent: Board Of Trustees Of The University Of Arkansas
20130052213 - Novel immunomodulatory peptide: The present invention relates a cleaved mammalian beta defensin with immunomodulatory properties. The cleaved or truncated peptides may be as potent as the full length mammalian beta defensins and may be used in the treatment of immunological and autoimmune disorders including but not limited to inflammatory bowel disease, and rheumatoid... Agent: Novozymes A/s
20130052215 - Tumor vaccine: The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic... Agent:
20130052216 - Targeted heterologous antigen presentation on calicivirus virus-like particles: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles... Agent: Ligocyte Pharmaceuticals, Inc.
20130052217 - Tumor vaccination involving a humoral immune response against self-proteins: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention... Agent:
20130052218 - Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus... Agent: Institut Pasteur And Centre National De La Recherche Scientifique
20130052221 - Dna-protein vaccination protocols: This invention provides a method of co-delivery of combination DNA and protein immunogenic compositions to enhance protective or therapeutic effects.... Agent: The Govt. Of The U.s, As Represented By The Sec. Of The Dept. Of Health And Human Services
20130052220 - Yeast-hiv antigen compositions and methods of using the same: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a... Agent: Globeimmune, Inc.
20130052222 - Influenza nucleic acid molecules and vaccines made therefrom: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided.... Agent: The Trustees Of The University Of Pennsylvania
20130052223 - Universal vaccine against h5n1 lineages: The present invention relates to a universal H5N1 vaccine. More specifically, the present invention relates to the identification of three H5N1 strains which cover the entire variants in the neutralizing epitopes of hemagglutinin among most H5N1 lineages. The present invention further relates a universal H5N1 vaccine that comprises the three... Agent: Temasek Lifesciences Laboratory Limited
20130052224 - Production of poliovirus at high titers for vaccine production: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and... Agent: Crucell Holland B.v.
20130052225 - Infectious dna vaccines against chikungunya virus: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated... Agent: Medigen, Inc.
20130052226 - Compositions and methods for preventing or treating a human parvovirus infection: The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.... Agent: The Government Of The Usa, As Represented By The Secretary, Department Of Health & Human Services
20130052228 - Attenuated fish vaccine following culture in iron limited media: Protection of fish from bacterial disease by vaccination with a live attenuated strain of the causative bacterium is enhanced when the attenuated strain has been grown in an iron-limited medium.... Agent: University Of Idaho
20130052227 - Hyperblebbing shigella strains: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.... Agent: Novartis Vaccines Institute For Global Health S.r.l.
20130052229 - Compounds and methods for diagnosis and immunotherapy of tuberculosis: Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA molecules encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable... Agent:
20130052230 - Salmonella vaccine: The present invention relates to novel Salmonella mutants, to a process for producing same and to vaccines containing same, wherein said Salmonella mutants are characterized in that they elicit a humoral response that can be distinguished from the humoral response elicited by the wild type strains. It is accordingly an... Agent: Universiteit Gent
20130052231 - Treatment methods utilizing stem cell mobilizers and immunosuppressive agents: The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a... Agent: The Johns Hopkins University
20130052236 - Composite polylactic acid/alginate surgical barrier: The present disclosure provides a medical assembly comprising a surgical barrier aspect comprising polylactic acid, and a hydrophilic mucoadhesive aspect, wherein the surgical barrier aspect is provided on a first side of the assembly and the mucoadhesive aspect is provided on a second side of the assembly. The disclosure also... Agent: Mast Biosurgery
20130052240 - Dermal micro-organs, methods and apparatuses for producing and using the same: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions... Agent: Medgenics Medical Israel Ltd.
20130052233 - Dry powder pharmaceutical compositions, its preparation process and stable aqueous suspension obtained from such composition: Pharmaceutical composition in a dry powder form comprising at least one hydrophobic active principle, at least one water-soluble excipient and at least one surfactant, wherein the particles in said dry powder state have a Volume Mean Diameter VMDd greater than the Volume Mean Diameter VMDw of particles in a suspension... Agent:
20130052234 - Edible strips: An edible oral strip composition includes a therapeutically effective amount of active agent(s) to provide at least one effect selected from a stimulating effect, an increased physical endurance, alleviate temporary fatigue, improve nervous system functions, and combinations of any of the foregoing. In additional embodiments, the edible strip composition includes... Agent: Purebrands LLC
20130052239 - Formulation: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.... Agent:
20130052238 - Gene delivery of oct4 and sirt1 and pharmaceutical compositions thereof: The present invention provides a method for decreasing the level of methylation of Oct4 promoter in a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention also provides a method for inducing cytoprotective responses of a target cell, comprising transfecting the... Agent: Taipei Veterans General Hospital
20130052235 - Herpes simplex virus nanoemulsion vaccine: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.... Agent: Nanobio Corporation
20130052232 - Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking: Methods for preparation of a heat stable hemoglobin based oxygen-carrier-containing pharmaceutical composition such that beta-beta cross-linking is favored are provided. Using the methods of the present invention, the oxygen affinity of the resultant molecule can be controlled so that hemoglobin based oxygen carriers tailored for specific applications can be produced.... Agent:
20130052237 - Methods of manufacturing viscous liquid pharmaceutical formulations: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.... Agent: Intarcia Therapeutics, Inc.
20130052241 - Non-aqueous taxane pro-emulsion formulations and methods of making and using the same: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.... Agent: Teikoku Pharma Usa, Inc.
20130052242 - Antiperspirant compositions and products having enhanced wetness protection and methods for making the same: Embodiments of antiperspirant compositions, products, and methods for making antiperspirant compositions and products are provided herein. The antiperspirant composition comprises an active antiperspirant compound and moisture absorbent particles. The moisture absorbent particles comprise aluminum starch octenylsuccinate and isopropyl titanium triisostearate.... Agent:
20130052243 - Composite material of inorganic nonmetallic mineral loaded with titania layer, preparation process and use thereof: The invention discloses composite materials, comprising an inorganic nonmetallic mineral as a support and a nanotitania layer loaded on the support, wherein the layer is comprised of a plurality of titania nanospheres, and the titania nanosphere is comprised of a plurality of nanotitania single particles. The invention also discloses composite... Agent:
20130052245 - Cosmetic and dermatological formulations of mntf peptides: The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.... Agent: Dermacare Neuroscience Institute
20130052246 - Cosmetic composition comprising boron nitride complex powder: A cosmetic composition includes a boron nitride complex powder in which particles of metal oxide are attached to at least a part of the surface of a base material consisting of boron nitride. The metal oxide is preferably a combination of titanium dioxide, yellow iron oxide, red iron oxide and... Agent: Chanel Parfums Beaute
20130052247 - Flexible article for nails with an improved adhesive layer: The present invention relates to a flexible article for application to the nails and/or false nails so as to make them up and/or care for them, the article comprising at least one adhesive layer, and being characterized in that said adhesive layer comprises at least two block copolymers, a tackifier... Agent: L'oreal
20130052244 - Stem cell compositions and methods: Provided are cosmetic compositions including a succulent plant stem cell extract and, optionally, an excipient. Also provided are methods of preparing a cosmetic composition. The methods include, for example, growing an Aloe vera callus to a predetermined size, preparing an extract from the callus, and mixing the extract with an... Agent:
20130052248 - Item of clothing for daily pharmacological treatment of a fungal infection: An item of clothing (10) for daily pharmacological treatment of a fungal infection, comprising: a textile material (20) to manage moisture when the item of clothing (10) is worn; microcapsules (30) grafted on the textile material (20); and antifungal agents encapsulated within the microcapsules (30) to pharmacologically treat the fungal... Agent:
20130052249 - Antimicrobial composition: An antimicrobial composition containing coniferous resin acids and/or their derivates, an antimicrobial polymer composition including coniferous resin acids and/or their derivates and processes for preparing thereof, and the use of the derivates of coniferous resin acids as an antimicrobial agent.... Agent: Taiga Polymers Oy
20130052250 - Compounds and methods for biofilm disruption and prevention: The invention relates to compounds, compositions and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces.... Agent: University Of Newcastle Upon Tyne
20130052251 - Composition and method for treating nosebleeds: A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.... Agent: Binyarco, LLC
20130052253 - Flavoring of drug-containing chewing gums: A chewing gum comprising at least one active pharmaceutical ingredient (API) with a core onto which is applied at least one inner polymer film coating and thereafter onto which is applied at least one outer hard coating. A preferred API is nicotine. Flavoring agents may be incorporated in the core,... Agent: Mcneil-ppc, Inc.
20130052252 - Hard coated confectionary having a consumable soft chewing core with a heat sensitive particulate active and method for making same: A hard coated confectionary product having a consumable, soft, high solids chewy core fortified with heat sensitive medicaments and vitamins with the core encapsulated in a hard consumable coating and a method for making the fortified confectionary is described.... Agent:
20130052255 - Nail discoloration and fungus treatment: A system and method for treating human nails afflicted with fungus, discoloration, or which are unusually thick is now disclosed. The system comprises a hydrogel moist pad or pad, a treatment agent comprising a metallic colloidal suspension having antifungal activity in an aqueous environment, and an adhesive for securing the... Agent: Spenco Medical Corporation
20130052256 - Nail discoloration and fungus treatment: A system and method for treating human nails afflicted with fungus is now disclosed. The system comprises a hydrogel dressing or pad, a topical agent consisting of a nanosilver treatment agent, a topical carrier in which said treatment agent is dispersed, and an adhesive for securing the hydrogel and treatment... Agent: Spenco Medical Corporation
20130052254 - System and method for a piezoelectric scaffold for tissue growth and repair: Provided is an electroactive structure and method for growing isolated differentiable cells comprising a three dimensional matrix of fibers formed of a biocompatible synthetic piezoelectric polymeric material, wherein the matrix of fibers is seeded with the isolated differentiable cells and forms a supporting scaffold for growing the isolated differentiable cells,... Agent: New Jersey Institute Of Technology
20130052257 - Antimicrobial hydrogel wound dressing: The antimicrobial hydrogel wound dressing is a swellable polymer gel made from about 7-9% (wt/vol) polyvinyl alcohol (PVA), preferably 8.9%, about 0.1% (wt/vol) polyvinyl pyrrolidone (PVP), and about 1-2% (wt/vol) agar, preferably 1%, the balance (about 90%) being distilled water, the foregoing contents being crosslinked by gamma radiation at a... Agent: King Saud University
20130052258 - Polypeptides and uses thereof: The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects... Agent: Xmedic Ab
20130052260 - Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and... Agent: Insmed Incorporated
20130052259 - Liposomes comprising amphipathic drugs and method for their preparation: The present invention provides a liposome having co-encapsulated in its intraliposomal aqueous core at least two amphipathic drugs, the liposomes being characterized by one of the following: the amphipathic drugs are co-encapsulated at a pre-determined ratio; the liposome comprises one or a combination of liposome forming lipids have a solid... Agent:
20130052261 - Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification... Agent: Globoasia, LLC
20130052264 - Controlled-release pharmaceutical composition including tamsulosin or pharmaceutically acceptable salts thereof, and oral formulation including the same: A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on the controlled-release polymer coating layer, wherein the average... Agent: Samyang Biopharmaceuticals Corporation
20130052262 - Dabigatran etexilate-containing oral pharmaceutical composition: The present invention relates to an oral pharmaceutical composition containing dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient.... Agent:
20130052263 - Pharmaceutical compositions with synchronized solubilizer release: Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.... Agent: LLPocine, Inc.
20130052265 - Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment: This invention relates to the field of chemical-pharmaceutical industry, specifically a new tuberculosis treatment that contains, as an active ingredient, 4-thioureido-iminomethylpyridinium perchlorate at a therapeutically effective and safe level and pharmaceutically acceptable excipients. In addition, this treatment relates to a method of the preparation of the new drug, providing a... Agent: Joint Stock Company "pharmasyntez"
20130052266 - Tablets containing a 1-(beta-d-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound: The present invention is directed to a tablet containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound in high drug loading, in particular, containing the compound ranging from 30 to 95% by weight of tablet and pharmaceutically acceptable additives.... Agent: Mitsubishi Tanabe Pharma Corporation
20130052268 - Compositions and methods for treatment of parkinson's disease: The present invention relates to methods for producing neural cells from progenitor or stem cells by activating both the Wnt1-Lmx1a/Lmx1b and the SHH-FoxA2 signaling pathways by, for example, increasing the biological activity of one or more of Wnt1, Lmx1a, Lmx1b, Otx2 and Pitx3 and one or more of SHH, FoxA2... Agent: The Mclean Hospital Corporation
20130052267 - Methods of inducing tissue regeneration: Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from... Agent:
20130052269 - Formulations for oral delivery of adsorbents in the gut: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment,... Agent: Da Volterra
20130052270 - Use of gold nanoclusters in ameliorating oxidate stress and/or aging: Disclosed herein is the novel use of a gold nanocluser for ameliorating oxidative stress and/or aging of a cultured cell or a subject having an oxidative stress and/or aging condition mediated by a vascular factor. The gold nanocluster has a particle size ranging from about 0.1 to 20 nm, and... Agent: Mackay Memorial Hospital
20130052271 - Compositions and methods for treating pain: The present invention provides compositions and methods for treating pain in mammals. A composition of the invention comprises one or more anti-inflammatory agents and optionally contains one or more anti-oxidants and immune system boosting agents.... Agent:
20130052272 - Pharmaceutical compositions and methods for the treatment and prevention of cancer: The present invention concerns pharmaceutical compositions and methods for treating proliferative diseases, e.g. cancer using intracellular and extracellular extracts. These cell extracts can direct epigenetic reprogramming of the cancer cells and thereby reverse their neoplastic phenotype... Agent:
20130052273 - Pharmaceutical composition comprising periplaneta americana or its ethanol extract and a method of using the same for treating inflammations: The present invention relates to Periplaneta Americana or its ethanol extract for the treatment of inflammation. Specifically, said inflammation includes cervical erosion, ulcerative colitis, skin ulcer, mucosal ulcer and postoperative condyloma acuminatum. Treating said disorders by Periplaneta Americana or its ethanol extract has the advantages of effectively reducing bleeding, shortering... Agent:
20130052274 - Nutritional compositions including exogenous vitamin k2: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium,... Agent: Nestec S.a.
20130052275 - Warming inch loss delivery system: This invention is a topical treatment for the skin, used for skin enhancement, firming, smoothing, refining and to reduce the appearance of cellulite; that has a self-warming or thermogenic effect comprised of a base combination of warming herbs (Ayurvedic), being any herbs that create a warming effect, combined with dietary... Agent:
20130052276 - Method for making an antimicrobial material from one-dimensional nanometer silver that does not accumulate in a human body: Disclosed is a method for making an antimicrobial material from 1D nanometer silver that does not accumulate in a human body. At first, 1D nanometer silver is mixed in hydrophilic solution to produce 1D nanometer silver solution. Then, adhesive is blended in the 1D nanometer silver solution to produce the... Agent: Chung-shan Institute Of Science And Technology Armaments, Bureau, Ministry Of National Defence
20130052277 - Process for the preparation of an antimicrobial article: Disclosed is a process for preparing an antimicrobial article, wherein a silver colloid is formed in situ as a result of the components employed. The process comprises the steps of (i) providing a liquid, which contains a soluble polar polymer in a solvent selected from certain polar organic solvents; (ii)... Agent: Polymers Crc Ltd.
20130052278 - Quick dissolve nutritional powder: The present disclosure provides a rapidly disintegrating orally administrable powder. The powder may include an active ingredient such as a dietary supplement. Methods of using the same are also provided herein.... Agent: Rich Vitamins LLC
20130052279 - Reverse micelle system comprising metal ions and use thereof: The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and metal ions. Reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of metal ions to target sites. It is advantageously useful in the pharmaceutical and... Agent: Medesis Pharma
20130052281 - Novel compounds: e
20130052280 - Use of thebromine for lowering central blood pressure: The use of theobromine for lowering central blood pressure and/or lowering central pulse pressure in humans and derived benefits, and compositions comprising theobromine.... Agent:
20130052282 - Insecticidal compositions and methods of using the same: Provided are mosquito larvicide compositions comprising a mineral oil and a methylated coconut oil. The compositions may further comprise a silicone and at least one surfactant. The compositions can kill mosquito larvae in swamps, floodwater areas, and other areas where mosquitoes develop. Further provided are methods for mosquito control. The... Agent:
20130052283 - Methods of treating a subject with benign prostate hyperplasia: The invention generally relates to methods of treating a male subject with a prostate condition, for example, benign prostate hyperplasia (BPH). In certain embodiments, the invention provides methods of treating a male subject with a prostate condition, which include administering a MetAP2 inhibitor at a dose that does not substantially... Agent:
20130052284 - Palm kernel oil-based intranasal composition and use: The present invention relates to the use of palm kernel oil as an active agent in natural, health-promoting products, particularly for intranasal use.... Agent:
20130052285 - Composition for controlling increase in blood glucose: The present application describes a composition for blood glucose control containing green tea extracts (GTE) with gallated catechins (GC) and macromolecule to prevent the intestinal absorption of GC.... Agent: Nuc Electronics Co., Ltd.
20130052286 - Composition for treatment of aesthenopia: e
20130052287 - Bioactive water fraction from gomphostema niveum: The present invention relates to a novel bioactive water fraction obtained from the leaves of an herb named Gomphostema niveum commonly found in North Eastern part of India, and which is useful for inhibiting the growth of malarial parasite Plasmodium falciparum. The present invention also relates to a method for... Agent: The Director General, Defence Research And Development Organisation
20130052288 - Collagen and elastin stimulating compositions and uses thereof: Methods and compositions for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ a botanical extract of Justicia ventricosa, Archidendron clypearia, Abrus fruticulosus, or combinations thereof and a cosmetically acceptable vehicle.... Agent: Avon Products, Inc.
20130052289 - Medicine containing extracts of ficus microcarpa for healing wounds of a diabetic patient: A medicine containing extracts of Ficus microcarpa for healing wounds including ulcerous wounds of a diabetic patient is provided. In one embodiment, the medicine is ointment, fluid, or spray for skin application. In another embodiment, the medicine is pill, powder, ointment, fluid, spray, tablet, or capsule for oral administration. In... Agent:02/21/2013 > 132 patent applications in 77 patent subcategories. patent applications/inventions, industry category
20130045160 - Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance: The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific... Agent: Industry-academic Coorporation Foundation, Yonsei University
20130045162 - Delivery system for specifically targeting cancer cells and method of use thereof: Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent.... Agent: Morehouse School Of Medicine
20130045161 - Methods and compositions for targeted imaging: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by... Agent: Signablok, Inc.
20130045163 - Treatment of metastatic tumors: The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment,... Agent: Morphotek, Inc.
20130045165 - 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators: as well as pharmaceutical compositions comprising compounds of formula I, are disclosed. These compounds and compositions are useful as treatments of conditions or diseases associated with binding opioid receptors including pain, obesity, hyperalgesia, inflammation, osteoarthritis, drug addiction, and cancer. These compounds and compositions are also useful as treatments for tardive... Agent: Kinentia Biosciences, LLC
20130045164 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient.... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20130045166 - Methods of polynucleotide detection: The present invention provides methods of detecting for the presence of a polynucleotide in vivo. These methods are particularly useful for performing identification and/or analysis of samples or specimens in which it is impossible, impractical, or undesirable to move or remove them from their current environment. Methods of practicing the... Agent: Monsanto Technology LLC
20130045167 - Staining composition: The invention is directed to a staining composition and to the use of the staining composition in staining ocular tissue. In a first aspect, the invention provides a staining composition comprising a vital dye and a density increasing compound chosen from the group consisting of water soluble polymers and small... Agent: Medical Technology Transfer Holding B.v.
20130045168 - Radiographic contrast agent for postmortem, experimental and diagnostic angiography: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast... Agent: Forim-x Ag
20130045169 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity: Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive and inflammatory diseases.... Agent: Chiesi Farmaceutici S.p.a.
20130045170 - Immunity boosting gum: A chewing gum is disclosed with immunity boosting properties to ward off illness and promote favorable health. The chewing gum begins with a gum base, to which various medicinal elements are added so that they can be released during mastication of the gum. The medicinal elements include zinc, Vitamin C,... Agent:
20130045171 - Bonding tissues and cross-linking proteins with naphthalimide compounds: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such... Agent: Alumend, LLC
20130045172 - Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by pbr, cb2, and nk2 receptors: The invention relates to the discovery that cis-epoxyeicosatraenoic acids (EETs) bind to and act as agonists of peripheral benzodiazepine receptor and the cannabinoid CB2 receptor. The invention provides methods of reducing symptoms of conditions whose activity is mediated by these receptors, including inhibiting anxiety, inhibiting the growth of cancer cells... Agent: The Regents Of The University Of California
20130045174 - Use of indole compounds as a cosmetic: wherein R1, R2 and R3 are identical or different and each is H or alkyl of 1-6 carbon atoms, R4 is H or methyl, R5 is phenyl or chlorophenyl, and/or physiologically acceptable salts thereof and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung
20130045175 - Use of skin permeation and retention enhancer compound in cosmetic and pharmaceutical compositions and cosmetic and pharmaceutical products containing said compound: The present invention relates to the use of a compound of general formula: wherein X is a CiO-24 carbon chain with “n” unsaturations wherein “n” is an integer from zero to 3 for the preparation of a cosmetic composition and a pharmaceutical composition to increase the skin permeation and retention... Agent: Natura Cosmeticos S.a.
20130045176 - Stable peptide-particle adduct compositions with improved surface adhesion: Compositions and methods comprising the use of stabilized peptide-particulate benefit agent adducts are provided having a multi-block peptide component and a particulate benefit agent, where the multi-block peptide comprises the general structure A1-(S1)p-(X1-Y)n—(X2)m-(S2)q-A2 or A1-(S1)p-(X1)m-(Y—X2)p-(S2)q-A2; wherein, A1 and A2 are body surface-binding domains; S1 and S2 are optional peptide spacers;... Agent: E. I. Du Pont De Nemours And Company
20130045177 - Method for inhibition of potential-dependent cation channel: An excellent potential-dependent cation channel inhibitor or an excellent masking agent is provided. Disclosed is a method for inhibiting a potential-dependent cation channel or a method for masking olfaction, both of which include administering an adamantane derivate represented by the following formula (1) or a salt thereof [wherein R′ and... Agent:
20130045179 - Combination therapy and methods for treatment and prevention of hyperproliferative diseases: The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of... Agent:
20130045181 - Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease: The present invention provides Chlamydia proteins and methods of use in treatment and immunization protocols as well as in diagnostic and detection assays.... Agent:
20130045180 - Vaccines, immunotherapeutics and methods for using the same: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases... Agent:
20130045183 - Boswellia oil, its fractions and compositions for enhancing brain function: The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species.... Agent: Laila Nutraceuticals
20130045182 - Polysaccharide based hydrogels: Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.... Agent:
20130045184 - Biologic female contraceptives: This invention provides, inter alia, commensal organisms engineered to express antibody fragments, which inhibit sperm motility or fertilization and compositions comprising the same. The present invention provides for the use of the engineered commensal organisms or compositions comprising the same as effective contraceptive means in females.... Agent:
20130045190 - Degradable microcapsules: The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is... Agent:
20130045185 - Strains and methods useful for mycotoxins: The disclosure relates to strains, compositions and methods for detoxifying a mycotoxin. In another embodiment, the disclosure relates to strains, compositions and methods for alleviating the gastrointestinal inflammatory response resulting from ingestion of mycotoxins. In one embodiment, the strains are Bacillus strains. In another embodiment, the strains are lactic acid... Agent: Dupont Nutrition Biosciences Aps
20130045186 - Method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.... Agent: The Trustees Of The University Of Pennsylvania
20130045187 - Methods and compositions of producing patient-specific multipotent neuronal stem cells: The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion.... Agent:
20130045189 - Methods of treating stroke through administration of ctx0e03 cells: The subject invention pertains to methods to enhance the therapeutic effects of cellular or drug treatment in various diseases and disorders. More particularly, the present invention provides methods of treating disorders by administering CTX0E03 cells to the patient, intravenously or intraarterially. The treatment is useful for neurodegenerative diseases, such as... Agent: University Of South Florida
20130045188 - Reduction of tgf beta signaling in myeloid cells in the treatment of cancer: Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
20130045191 - Novel immunotherapy against several tumors including gastrointestinal and gastric cancer: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as... Agent: Immatics Biotechnologies Gmbh
20130045192 - Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also... Agent: Alexion Pharmaceuticals, Inc.
20130045193 - Compositions and methods for the prevention of cardiovascular disease: The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ10,... Agent:
20130045194 - Delivery of cholesteryl ester to steroidogenic tissues: Disclosed are compositions and methods for treating conditions characterized by low HDL-CE which can lead to decreased delivery of cholesteryl ester to steroidogenic tissues, reducing the organ's ability to produce steroids especially during periods of demand, stress and or systemic inflammatory response syndrome.... Agent: Alphacore Pharma, LLC
20130045195 - Proteases for degrading gluten: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.... Agent: Alvine Pharmaceuticals, Inc.
20130045196 - Enzymatic wound debriding compositions with enhanced enzymatic activity: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.... Agent: Healthpoint, Ltd.
20130045197 - Marine based cosmetic active ingredients and use thereof: The present invention relates to a cosmetic and/or pharmaceutical active component for stimulating proteasome activity of skin cells comprising the broth obtained by inoculating a biomass of the algae, Gracilaria spp., particularly the algae, Gracilaria tikvahiae, with a yeast culture, and allowing fermentation of the biomass to produce a fermentation... Agent: Basf Corporation
20130045199 - Antibody preparations: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine... Agent: Biotest Ag
20130045198 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for... Agent: Celera Corporation
20130045202 - Anti-pd-l1 antibodies and articles of manufacture: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.... Agent: Genentech, Inc.
20130045204 - Fluorinated bisphenol ether compounds and methods for their use: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, and wherein at least one of R1, R2, R3, R4 or R5 is F, are provided. Uses of such compounds for treatment of various indications,... Agent: British Columbia Cancer Agency Branch
20130045201 - Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.... Agent: Genentech, Inc.
20130045200 - Methods of using anti-pd-l1 antibodies and their use to treat infection resulting from t-cell dysfunction: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.... Agent: Genentech, Inc.
20130045203 - Uses of noscapine and derivatives in subjects diagnosed with fap: This disclosure relates to methods of treating or preventing cancer comprising administering a pharmaceutical composition comprising noscapine or noscapine derivatives to a subject diagnosed with a mutated adenomatous polyposis coli (APC) gene.... Agent: Emory University
20130045205 - Methods and compositions related to glycoprotein-immunoglobulin fusions: Disclosed herein are compositions and methods for eliciting immune responses against HCV antigens. In particular embodiments, the compounds and methods elicit immune responses against all or a segment of HCV glycoprotein E1 and/or HCV glycoprotein E2.... Agent:
20130045206 - Antibodies directed against the transferrin receptor and uses thereof for immunotherapy of iron-dependent tumours: The present invention relates to a molecular structure characterised in that said structure includes at least one amino acid sequence selected from: SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7,... Agent:
20130045207 - Antibody against serotype g lipopolysaccharide of pseudomonas aeruginosa: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype G and which have excellent antibacterial activities in... Agent: Meiji Seika Pharma Co., Ltd.
20130045208 - Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to... Agent: Haptogen, Ltd.
20130045210 - Pharmaceutical composition for treating and/or preventing cancer: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a... Agent:
20130045209 - Wnt-binding agents and uses thereof: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human Wnt(s) are provided. A conserved domain within Wnt that is suitable as a target for anti-cancer agents is also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to... Agent: Oncomed Pharmaceuticals, Inc.
20130045211 - Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are... Agent: Contrafect Corporation
20130045212 - Biological materials and uses thereof: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents.... Agent:
20130045213 - Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity: The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the... Agent: Avaxia Biologics, Inc.
20130045215 - Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans: A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as chemotherapy related... Agent: University Of Southern California
20130045214 - P53 modulator and cancer target: Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and/or biological activity are described. In particular, methods of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and... Agent:
20130045217 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting... Agent: Zora Biosciences Oy
20130045216 - Method for treating amyloid disease: Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (Aβ) or on dialysis of blood or... Agent: New York University
20130045219 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable... Agent: Ucb Pharma S.a.
20130045218 - Fc receptor binding proteins: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.... Agent: Dyax Corp.
20130045220 - Microvesicle membrane protein and application thereof: Microvesicles play essential roles in disease progression. The present invention provides a novel microvesicle membrane protein and application thereof. Disclosed is method comprises phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binding agents for microvesicle isolation, analysis, or binding for disease diagnosis or treatment.... Agent:
20130045222 - Compositions and methods for enhancing immune responses to vaccines: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.... Agent: Vical Incorporated
20130045224 - Immunostimulatory compositions and methods of use thereof: Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type II arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects.... Agent: Comvita New Zealand Limited
20130045223 - Methods and compositions to protect aquatic invertebrates from disease: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal.... Agent: Harrisvaccines, Inc.
20130045221 - T-cell receptor capable of recognising an antigen from cytomegalovirus: The present invention provides a T-cell receptor (TCR) which binds to a peptide from the cytomegalovirus (CMV) phosphoprotein pp65 having the amino acid sequence NLVPMVATV (SEQ ID No. 1) when presented by a major histocompatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR,... Agent: Ucl Business PLC
20130045225 - Synthetic antigen based on the ligand domain of the plasmodium vivax duffy binding protein: The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite Plasmodium vivax. The compositions are based on the ligand domain of Plasmodium vivax Duffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant... Agent: University Of South Florida ( A Florida Non-profit Corporation )
20130045226 - Method for forming and extracting solid pellets comprising oil-containing microbes: A process including: (a) mixing a microbial biomass, comprising oil-containing microbes, and at least one grinding agent capable of absorbing oil, to provide a disrupted biomass mix; (b) blending at least one binding agent with said disrupted biomass mix to provide a fixable mix capable of forming a solid pellet;... Agent: E I Du Pont De Nemours And Company
20130045227 - Uses of red yeast rice in treating dengue virus infection: This invention provides a method of using red yeast rice fermented product to treat a subject having a disease caused by dengue virus. In one embodiment, the red yeast rice is prepared with the yeast Monascus purpureus.... Agent: Eu Yan Sang International Limited
20130045228 - Vaccine for protection against lawsonia intracellularis: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being... Agent: Intervet International B.v.
20130045229 - Anti-viral compounds: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.... Agent: Kineta, Inc.
20130045230 - Composition containing hcmv particles: The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic.... Agent: Vakzine Projekt Management Gmbh
20130045231 - Immunogenic composition: Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.... Agent:
20130045232 - Mucosal vaccines: m
20130045233 - Novel allergen: An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and... Agent: Phadia Ab
20130045235 - Autologous biological cancer vaccine: The present disclosure relates to an autologous biological cancer vaccine and to a method for preparing the same. The vaccine of the present application is a biological vaccine obtained from overexpressed proteins in the serum of cancer patients, proteins to which have been added immunological adjuvants such as an attenuated... Agent: Universidad Manuela Beltran
20130045234 - Neutralizing factors as vaccine adjuvants: The present invention is a vaccine adjuvant composed of a vaccinia virus vector that encodes a polypeptides capable of neutralizing immune suppressive factors thereby enhancing or stimulating an immune response to a vaccine.... Agent:
20130045236 - Diagnostic and therapeutic uses of soluble fc-epsilon receptor i for ige-mediated disorders: The present disclosure is based in part on the finding that sFcεRI is a novel biomarker for IgE-mediated disorders. Methods for diagnosing, treating and/or monitoring IgE-mediated disorders are also described. The disclosure further provides assays to detect sFcεRI in a sample.... Agent:
20130045245 - Apixaban formulations: Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.... Agent: Bristol-myers Squibb Company
20130045252 - Apparatus for the arrestment and retention of bromhidrosis: An apparatus for adsorption of body odour comprising: an activated carbon layer for adsorbing body odour; a first material layer; and wherein the activated carbon layer is coupled to the first material layer.... Agent:
20130045237 - Combination pharmaceutical composition and methods of treating and preventing the infectious diseases: The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different... Agent:
20130045240 - Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.... Agent: Abraxis Bioscience, LLC
20130045242 - Dextrin hydrogel for biomedical applications: A hydrogel formulation of oxidized dextrin is reticulated with adipic acid dihydrazide, which may embody polysaccharides, proteins, nanogels, granular materials, bioactive molecules and cells for tissue regeneration and controlled drug delivery. A hydrogel can be injectable, highly biocompatible and biodegradable, for tissue regenerative applications, performing simultaneously as a vehicle e.g.... Agent: Universidade Do Minho
20130045238 - Emulsions for transdermal delivery: The present invention generally relates to transdermal delivery and, in particular, to transdermal delivery using nanoemulsions and other emulsions. In one aspect, the present invention is directed to emulsions comprising a first, continuous phase and a second, discontinuous phase. The first phase may be an aqueous liquid and the second... Agent: Agency For Science, Technology And Research
20130045246 - Enclosing materials in natural transport systems: Edible or potable substances can be transported in biodegradable vessel.... Agent:
20130045247 - Fatty acid conjugates of quetiapine, process for making and using the same: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also... Agent: Kempharm Inc.
20130045249 - Glycosaminoglycans: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.... Agent: Agency For Science, Technology And Research
20130045239 - Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists: A method of modulating the pharmacodynamic effect of a GC-C receptor agonist polypeptide formulation in a subject in need of such treatment is disclosed, The method comprises administering the GC-C receptor agonist polypeptide formulation to the subject before the ingestion of food.... Agent: Ironwood Pharmaceuticals, Inc.
20130045244 - Modified adam disintegrin domain polypeptides and uses thereof: Modified ADAM (A Disintegrin and Metalloproteinase) Polypeptides (MAPs) are provided. Methods are provided for administering MAPs for anti-angiogenesis and anti-tumor growth activity. Compositions of the invention are also useful for treating endothelial cell dysfunction and for diagnosis of integrin-related conditions.... Agent: University Of Southern California
20130045243 - Nanogenomics for medicine: sirna engineering: Described herein are materials and methods for the delivery of siRNA and the production of nanoparticles useful for the delivery of siRNA. Methods of treating a disease or disorder using the nanoparticles described herein also are disclosed.... Agent: George Mason Intellectual Properties, Inc.
20130045253 - Oral antidepressant formulation with reduced excipient load: Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer... Agent:
20130045248 - Personal care compositions comprising an anti-irritation agent: A personal care composition comprising an anti-irritation agent such as a zinc pyrithione, a zinc salt or a combination thereof.... Agent:
20130045251 - Pharmaceutical composition for improving solubility of prasugrel and its preparation method: A pharmaceutical composition containing prasugrel and its pharmaceutically acceptable salts, and methods for preparing the same are disclosed. The pharmaceutical composition improves the dissolution rate of prasugrel and its salts at high pH by using solid dispersion technology, inclusion technology or adding surfactants.... Agent: Jiangsu Hansoh Pharmaceutical Group Co., Ltd
20130045241 - Stabilized aqueous dispersion of folpet analogues, method of preparing the same and composition thereof: An aqueous dispersion having a mixture of a hydrolysis-sensitive biocide, an iodo-derived hydrophobic biocide and an inert carrier dispersed in water. The iodo-derived hydrophobic biocide forms a complex with the inert carrier and the hydrolysis-sensitive biocide that is dispersible in water. The hydrophobic coating includes an inert carrier and the... Agent: Isp Investments Inc.
20130045250 - Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative: A suspension and a cake composition are provided in which agglomeration of the active ingredient that is caused when silicone oil and/or silicone oil derivative is contained therein can be suppressed without a special treatment, such as sonication. The suspension contains, in a dispersion medium, an active ingredient of a... Agent: Otsuka Pharmaceutical Co., Ltd.
20130045257 - Aerosol shave composition comprising a hydrophobical agent forming at least one microdroplet and an anti-irritation agent: An aerosol shave composition, preferably a post foaming shave gel, comprising a hydrophobic agent, such as a silicone, in the form of a microdroplet having a particle size from about 0.15 microns to about 10 microns and an anti-irritation agent such as zinc pyrithione, and a method of making.... Agent:
20130045261 - Anhydrous foam comprising silica: An anhydrous cosmetic composition in the foam form includes at least one pasty fatty substance in a content of between 10 and 50% by weight, at least one wax in a content of between 4 and 20% by weight, at least one nonvolatile oil in a content of between 40... Agent: L'oreal
20130045254 - Compositions and methods for tinting keratin material: A cosmetic composition comprising at least one volatile solvent, at least one crosslinked silicone film former, at least one silicone gum, and at least one pigment composition present in an amount sufficient to provide the cosmetic composition with a pigment contrast ratio of greater than 35 and a method for... Agent:
20130045258 - Cosmetic product comprising uv-blocking cosmetic composition impregnated into expanded urethane foam: The present invention relates to a cosmetic product comprising a UV-blocking W/O or O/W composition of low viscosity packaged in a compact-type container. More specifically, the invention relates to a UV-blocking cosmetic product prepared by impregnating a UV-blocking W/O or O/W cosmetic composition of low viscosity into expanded urethane foam,... Agent: Amorepacific Corporation
20130045259 - Cosmetic product comprising uv-blocking cosmetic composition impregnated into expanded urethane foam: The present invention relates to a cosmetic product comprising a UV-blocking W/O or O/W composition of low viscosity packaged in a compact-type container. More specifically, the invention relates to a UV-blocking cosmetic product prepared by impregnating a UV-blocking W/O or O/W cosmetic composition of low viscosity into expanded urethane foam,... Agent: Amorepacific Corporation
20130045255 - Personal care methods: Methods are provided to enhance deposition of zinc pyrithione.... Agent:
20130045256 - Shave preparations comprising an anti-irritation agent: A shave preparation comprising water; one or more lipophilic skin conditioning agents; one or more thickening agents; one or more emulsifying agents; and one or more lubricants, and an anti-irritation agent such as zinc pyrithione.... Agent:
20130045260 - Solid emulsified cosmetic: An object of the present invention is to provide a solid emulsified cosmetic that stably contains a large amount of a high refractive index silicone oil; gives a lustrous finish; and has a skin irregularity-correcting effect. Thus, a solid emulsified cosmetic of the present invention is characterized by comprising: (A)... Agent: Shiseido Company, Ltd.
20130045262 - Sedative for external use, and sedative sheet, and textile, clothing, wall material, and hyperthermia equipment, brain vitalization sheet, brain vitalization small pillow: Disclosed are a sedative for external use, and sedative sheet, and textile, clothing, wall material, and hyperthermia equipment, brain vitalization sheet, brain vitalization small pillow which are with high productivity, adaptive for various shape and various treatment style for patients with pain, and with high treatment effect, comparing with conventional... Agent:
20130045264 - Antifouling coating composition and uses of the same: s
20130045263 - Personal care compositions having dried zinc pyrithione-polymer aggregates: Personal care composition and methods are included with respect to a dried zinc pyrithione-polymer aggregate.... Agent:
20130045265 - Antimicrobial strap: The invention discussed is a durable Antimicrobial Strap made using a polymer material, including plastics or vinyl, or a combination thereof, which have been enhanced through the integration of antimicrobial material adapted to kill microbes. The Antimicrobial Strap may be used in applications including but not limited to gait belts,... Agent:
20130045266 - Method for preparing polymeric biomaterials having immobilized drug delivery system comprising bioactive molecules loaded particle carrier: A new polymeric material for biological tissue regeneration or treatment with a drug delivery system which contains therapeutic agents and/or bioactive molecules to reduce infection and inflammatory reaction at a wound site and maximize tissue regeneration and wound healing is provided. The new bioactive molecule-loaded polymeric material is prepared by... Agent: Kyungpook National University Industry-academic Cooperation Foundation
20130045268 - Abuse-resistant mucoadhesive devices for delivery of buprenorphine: The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.... Agent:
20130045267 - Methods of using agents that modulate claudin expression: Methods are provided for modulating expression of claudin-1 and/or claudin-23, for purposes of regulating formation of tight junctions in keratinocytes or other types of cells such as antigen presenting cells (e.g., dendritic cells and Langertians cells), by either increasing or decreasing expression of claudin-1 and/or claudin-23. Also provided are transdermal... Agent: University Of Rochester
20130045269 - Formulations and methods for wound treatment: The present application relates to formulations and methods for treating wounds, including chronic wounds. Suitably, the formulations comprise antibiotics and lawsonia inermis extract in various amounts. In embodiments, the formulations are formulated as sprays or gels that can be applied directly to the wound or to a wound dressing that... Agent: Sorush LLC
20130045272 - Agent for treating myelofibrosis: Disclosed is a substance delivery carrier for an extracellular-matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed in an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular-matrix-producing cell in the bone marrow.... Agent: Nitto Denko Corporation
20130045270 - Method of use of stabilized growth factor in skin care: Dermatologic compositions for therapeutic use, containing a growth factor, or a growth factor purified from transgenic plants, or animal, bacterial, yeast or insect cells, or a mixture of growth factors in purified form, for treatment of various dermatological conditions and diseases. The pharmaceutical compositions are suitable for treatment of sensitive... Agent:
20130045271 - Steroid hormone delivery systems and methods of preparing the same: The present invention is directed to steroid hormone delivery systems and methods of preparing the same. In particular, the steroid hormone delivery systems provided include a primary construct having one or more hydrophobic steroid hormone esters in the form of a liposome, a lipid particle, a micelle, an emulsion or... Agent: Monosol Rx, LLC
20130045274 - Bacteriotherapy for clostridium difficile colitis: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed... Agent: Mikrobex
20130045273 - Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds: Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds to maintain or increase the levels of cellular GSH in the body are described. In some instances, the nutritional supplements can increase both the levels of GSH, vitamin C, GST activity, and antioxidant protection in the blood. The... Agent:
20130045275 - Sustained-release chitosan capsules comprising chitosan and phytic acid: The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according... Agent: Industry-academic Cooperation Foundation, Yonsei University
20130045276 - Sustained release aminopyridine composition: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Alkermes Pharma Ireland Limited
20130045277 - Biocompatible device: Disclosed is a biocompatible device surface-coated on the base material thereof with a biocompatible polymer layer having antithrombogenicity and endothelialization activity, and embedded in or attached to a living body for use. The polymer layer comprises a polymer matrix formed by the crosslinking of a cell-adhesive peptide-containing polymer.... Agent:
20130045278 - Skin formulation, preparation and uses thereof: Serum compositions for application to skin are described which contain an amniotic fluid extract in combination with embryonic stem cells. Formulations containing the serum composition are also described. The serum compositions and formulations may be applied to skin for treatment of symptoms of aging, wounds, burns, scars or other skin... Agent: Golden Pearl Investment LLC
20130045279 - Analgesic and anti-inflammatory composition: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of... Agent: Cambridge Scientific Pty Ltd
20130045280 - Product and treatment for hepatitis c and sclerosis of the liver and methods of forming the product: A method for formulating a treatment for hepatitis C and sclerosis of the liver is disclosed. The method may comprise steps of processing bone marrow of a bone of a bird. To prepare the composition for feeding to a mammal, the mammal is prepared by purging the mammal's intestines of... Agent:
20130045281 - Prepartion of silver ion: Disclosed is a process for preparing silver ions (Ag+) comprising treating element metal silver (Ag0) under high temperature and high pressure, and quickly cooling to directly obtain the silver ions (Ag+).... Agent:
20130045282 - Method of manufacturing the silica nanopowders with fungicidal properties, especially for polymer composites: Method of manufacturing the silica nanopowders with fungicidal properties, consists in that the silica gel is obtained by sol-gel method from the reaction mixture containing tetraalkoxysilane and aliphatic alcohol, in the presence of ammonium compound, and thereafter the thermodegradable copper(II) salt a compound from the group of carbofunctional alkoxysilanes, and... Agent:
20130045283 - Compositions for and methods of controlling olfactory responses to odorants: A composition, system and method for modifying an olfactory response to an odorant is disclosed. In some embodiments, the composition includes crystalline metal nanoparticles dispersed in an aqueous medium. The composition is applied to olfactory tissues using a suitable applicator or dispenser. The metal nanoparticles are believed to interact with... Agent: Auburn University
20130045285 - Methods of enhancing skin hydration and improving non-diseased skin: A method of enhancing skin hydration, the method including applying a rinse-off personal care composition comprising at least one of a zinc-containing material and a pyrithione material to non-diseased skin of an individual.... Agent:
20130045284 - Methods of enhancing skin hydration and treating non-diseased skin: Methods of enhancing skin hydration include applying a leave-on moisturizing composition comprising a zinc-containing material and/or a pyrithione material.... Agent:
20130045286 - Pyrrolopyridines as kinase inhibitors: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Array Biopharma Inc.
20130045287 - Treatment for concussion using gallium compounds: Disclosed is a method of treating concussion or other brain trauma in humans or other mammals by administering an effective dose of a gallium compound or gallium complex to the injured human or other mammal. The gallium compound may comprise, e.g., gallium nitrate, a docosahexaenonic acid salt of gallium with... Agent:
20130045288 - Method for treating prostate cancer: A method for treatment of a human subject with prostate cancer is disclosed. The method comprises administering an anti-prostate cancer effective amount of a composition obtained by the extraction of fresh citrus fruit peels in sake.... Agent:
20130045289 - Composition for promoting the activity of peroxisome proliferator-activated receptor-delta: Disclosed is a composition for promoting the activity of peroxisome proliferator-activated receptor-δ (PPAR-δ), which contains Artemisia vulgaris extracts or Artemisia capillaris extracts as active ingredients. The composition is effective in strengthening muscles, improving endurance and memory, and preventing and alleviating the symptoms of dementia or Parkinson's disease.... Agent: Amorepacific Corporation
20130045290 - Dermal rejuvenation compositions and methods: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol... Agent: Kate Somerville Skincare, LLC
20130045291 - Anti-allergic composition: It is to provide a composition derived from lactic acid bacteria having an anti-allergic effect (an effect of suppressing allergic symptoms such as hay fever) synergistically, and a food product, pet food, etc. containing the composition. It is to prepare a composition having an anti-allergic action, containing Lactobacillus crispatus KT-11... Agent: Kitii Co., Ltd.02/14/2013 > 161 patent applications in 96 patent subcategories. patent applications/inventions, industry category
20130039847 - Liposomes for pulmonary administration: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected... Agent: Justus-liebig-universitat Gieben
20130039848 - Fluorescent silica-based nanoparticles: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary... Agent: Sloan-kettering Institute For Cancer Research
20130039849 - Adenocarcinoma specific antibody sam-6, and uses thereof: The present invention features a polypeptide, such as an antibody produced by the hybridoma SAM-6 and its use in the treatment and diagnosis of neoplasms.... Agent: Patrys Limited
20130039850 - Heterologous antibodies which bind human cd4: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.... Agent: Genpharm International, Inc.
20130039852 - Methods of targeting cells for diagnosis and therapy: Methods of making bispecific binding complexes and nanopolymers coupled to detection and/or therapeutic agents are disclosed. Also disclosed are methods of using such bispecific binding complexes and nanopolymers for detecting and treating cells.... Agent: Northeastern University
20130039851 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T... Agent: Aegis Theraperutics, LLC
20130039853 - Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are... Agent:
20130039855 - Aptamer to fgf2 and use thereof: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing... Agent:
20130039854 - Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the... Agent: University Of Southern California
20130039857 - Methods of suppressing cancer, increasing weight loss and/or increasing insulin sensitivity: The present invention provides methods for determining if an agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity, comprising contacting Fyn and/or LKB1 with the agent and determining if the agent inhibits Fyn kinase activity or inhibits the interaction between Fyn and LKB1,... Agent:
20130039856 - Products and methods: The present invention concerns medicaments for slowing ageing. The medicaments can include an inhibitor of microbial folate biosynthesis as well as agents capable of reducing folate uptake by an animal. Examples of such medicaments include inhibitors that reduce the activity of an enzyme in the folate biosynthesis pathway, such as... Agent: University Of Durham
20130039858 - Nir materials and nanomaterials for theranostic applications: Novel fluorescent dye comprising metal oxide nanoparticles are prepared where the nanoparticles are as small as 3 nm or up to 7000 nm in diameter and where the dye is bound within the metal oxide matrix. In some embodiments the invention, novel dyes are covalently attached to the matrix and... Agent: University Of Florida Research Foundation, Inc.
20130039861 - Dye conjugated peptides for fluorescent imaging: The present application discloses compositions and methods of use of dye conjugated peptides for fluorescent detection, diagnosis and/or imaging. In preferred embodiments, the compositions comprise a DNL complex comprising an anti-hapten antibody or antigen-binding fragment thereof conjugated to an AD moiety and a DDD moiety conjugated to an antibody or... Agent: Immunomedics, Inc.
20130039860 - Fluorescent imaging with substituted cyanine dyes: e
20130039859 - Passivated nanoparticles: Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein.... Agent:
20130039862 - Compounds of dibenzylidene sorbitol ester type, process of preparation, use, compositions comprising them and cosmetic treatment method: The invention also relates to their process of preparation, to their use in structuring lipophilic media, in particular oils, to the cosmetic or pharmaceutical compositions comprising them and to a cosmetic treatment method employing them.... Agent: L'oreal
20130039863 - Methods of controlling the breeding behavior of butterflies: Methods of controlling the feeding and/or breeding behavior of a target insect are disclosed in which a host plant is provided a substantial distance from a plant of interest, chemical attractant that induces the target insect to lay eggs on the host plant is applied to the host plant, application... Agent: University Of The West Indies A Regional Institution Established By Royal Charter
20130039864 - Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof: The disclosure relates to a non-intravenous dosage for administration of a liquid biologically active agent. The dosage form contains a solid formulation of the liquid biologically active agent, e.g. propofol, in intimate association with at least one stabilizing agent, e.g. an amphiphilic polymer or surfactant. A liquid biologically active agent... Agent:
20130039866 - Composition for the prophylaxis of candidiasis: The invention solves the problem of the practical realization of an effective prophylactic composition which uses available and safe components and which can be recommended for preventing the growth of candidiasis of the skin and/or mucous membranes in humans in the following risk group: sufferers of diabetes mellitus, people with... Agent: Obshchestvo S Ogranichennoj Otvetstvennostyu "wds"
20130039867 - Oral care composition comprising stannous and nitrate ions: An oral care composition comprising a) an aqueous phase; b) stannous ions solvated in the aqueous phase; c) nitrates solvated in the aqueous phase; wherein the total content of said nitrates is such that the molar amount of nitrogen in the aqueous phase, measurable as nitrate, is less than 2... Agent:
20130039865 - Oral care compositions and methods: Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of... Agent:
20130039868 - Dentifrice composition: A teeth whitening dentifrice that enhances the shades of teeth with only a short application on the teeth. The dentifrice disrupts the surface tension between the teeth and the stains to provide with the aid of commonly known mechanical brushing and rising methods. 1 to 3 shades of whiter teeth.... Agent:
20130039869 - Rosacea treatments and kits for performing them: Regimen for the treatment of rosacea include the application of an anti-redness composition to at least a portion of the cleansed area of skin afflicted with rosacea. The regimen may include the application of one or more of a polymetal complex, a composition containing metronidazole, and/or a protective composition. Kits... Agent: Jr Chem, LLC
20130039871 - Aqueous composition contained in container: Provided is an aqueous composition contained in a container, where water evaporation of the aqueous composition contained in a container is inhibited, and thereby the contents are prevented from solidifying or changing in properties. As a result, excellent long-term stability is obtained, and even when the container is a spray... Agent: Kao Corporation
20130039870 - Cosmetic or dermatological preparations with a content of one or more thiazole derivates: Cosmetic or dermatological preparations having an effective content of one or more thiazoles of the general formula... Agent: Beiersdorf Ag
20130039872 - Ester preparation with after-treatment: The present invention relates to a process for the preparation of an ester in a reactor, a device, a process for the preparation of a thermoplastic composition comprising the ester prepared according to the invention, a process for the production of a shaped article comprising the ester according to the... Agent:
20130039875 - Shampoo containing a dendritic macromolecule and a gel network: A hair care composition comprising: i) a cleaning phase comprising a cleansing anionic surfactant which is a salt and comprises an alkyl group with from 8 to 14 carbons; ii) an aqueous conditioning gel network having no overall charge or is anionic, the gel network comprising: (a) fatty material; (b)... Agent:
20130039873 - Hair and skin conditioning compositions: Compositions for providing hair and skin care benefits, such as smoothing, anti-static control, color protection, frizz control and moisturization are disclosed. The compositions maintain clarity, show no separation upon standing, and remain flowable liquids at room temperature. The compositions comprise a silicone or hydrocarbon component having a viscosity of from... Agent: Kao Corporation
20130039874 - Mascara containing an aqueous dispersion of polyurethane and an acrylic film former: The invention relates to a composition comprising at least one aqueous polyurethane dispersion and at least one acrylic film forming agent.... Agent: L'oreal S.a.
20130039876 - Perfume compositions: Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A... Agent: Givaudan Nederland Services B.v.
20130039877 - Perfume compositions: Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A... Agent: Givaudan Nederland Services B.v.
20130039879 - Ophthalmic compositions containing a synergistic combination of two polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.... Agent:
20130039880 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from... Agent: Cerulean Pharma Inc.
20130039878 - Triple cross-linked collagen, method of manufacturing the same, and use thereof: The present invention relates to a method for manufacturing a triple cross-linked collagen, which comprises the following steps: providing a soluble collagen sample; mixing the collagen sample with a first cross-linking agent to form a one cross-linked collagen; mixing the first cross-linked collagen with a second cross-linking agent to form... Agent: Sunmax Biotechnology Co., Ltd.
20130039881 - Combination for the treatment of radiation- or chemotherapy-induced mucositis: The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of mucositis induced by radiation or chemotherapy.... Agent: Professional Dietetics S.r.l
20130039883 - Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment: Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor ligand in conjunction with an effective amount of a compound described herein, for example, a cucurbitacin (I) or... Agent: The United States Of America
20130039882 - Method to mitigate injury from radiation exposure: Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.... Agent: Henry Ford Health System
20130039886 - Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity: β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as... Agent: The University Of Birmingham, Of Edgbaston
20130039884 - Compositions and methods for improving production of recombinant polypeptides: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical... Agent: Amunix Operationg Inc.
20130039885 - Leukotoxin e/d as a new anti-inflammatory agent and microbicide: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by... Agent: New York University
20130039887 - Methods of identifying and using anti-viral compounds: Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.... Agent: Kineta, Inc.
20130039888 - Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders: The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as... Agent: Nationwide Children's Hospital Inc.
20130039889 - Recombinant microorganisms: The invention relates to a recombinant microorganism comprising a transgene encoding angiogenin and optionally follistatin, a food product, beverage product or animal feed produced from or comprising said microorganism and uses thereof.... Agent: Murray Goulburn Co-operative Co. Limited
20130039890 - Treatment of tumors with genetically engineered herpes virus: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.... Agent: Arch Development Corporation
20130039895 - Mir-150 for the treatment of blood disorders: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.... Agent: Massachusetts Institute Of Technology
20130039894 - Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury: The present invention relates to polypeptides transiently activating Ras homolog gene family member A (RhoA) GTPase, polynucleotides encoding said polypeptides and pharmaceutical compositions comprising said polypeptides or said polynucleotides. The present invention further relates to the use of said polypeptides, said polynucleotides or said pharmaceutical compositions for long-term treatment of... Agent:
20130039891 - Poxviral oncolytic vectors: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.... Agent: Transgene S.a.
20130039892 - Adherent stromal cells derived from plancentas of multiple donors and uses thereof: Pharmaceutical compositions comprising adherent stromal cells (ASCs) are provided. The ASCs are obtained from at least two donors. Articles of manufacture comprising the pharmaceutical compositions together with a delivery device for administering the ASCs to a subject are also provided. Also provided are methods of treating various diseases and conditions... Agent: Pluristem Ltd.
20130039893 - Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom: The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells.... Agent: Cellresearch Corporation Pte Ltd
20130039896 - Pharmaceutical kits comprising mesenchymal stem cells: A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration... Agent: Quy Biosciences Limited
20130039897 - Compositions and methods for regulating neutrophil movement and neutrophil numbers in a body region: The disclosure relates to compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium autocrine proliferation repressor A (AprA) region. The disclosure also relates to a method of reducing the number of neutrophils in a body... Agent: The Texas A&m University System
20130039898 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof: Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods... Agent: Biomarin Pharmaceutical Inc.
20130039899 - Methods and devices for applying tissue sealants and adhesives: Methods of application and devices thereof for tissue adhesives. The adhesives comprise a plurality of components which are provided separately but which are mixed together to form the adhesive. At least one component is a crosslinkable protein solution and at least one other component is a crosslinking material solution. The... Agent: Lifebond Ltd.
20130039900 - Compositions and methods for altering cocaine esterase activity: The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.... Agent: The Regents Of The University Of Michigan
20130039901 - Treatment of pompe's disease: The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.... Agent: Genzyme Therapeutic Products Limited Partnership
20130039902 - Non-neurotoxic plasminogen activating factors for treating of stroke: The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.... Agent: H. Lundbeck A/s
20130039903 - Eczema treatment: A use of a composition including lactoferrin and/or immunoglobulin for minimizing the severity of one or more symptoms associated with eczema.... Agent: Probiotec Limited
20130039905 - Diazoxide for use in the treatment or prevention of a central nervous system (cns) autoimmune demyelinating disease: The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburg's acute M S, Balós's concentric sclerosis, acute disseminated encephalomyelitis (ADEM),... Agent: Neurotec Pharma, S.l.
20130039907 - Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.... Agent: Kalobios Pharmaceuticals Inc.
20130039909 - Predicting response to a her inhibitor: e
20130039908 - Prognostic markers and methods for prostate cancer: The present invention relates to methods and compositions for the diagnosis, prognosis and treatment of neoplastic disorders. Some embodiments include methods, compositions, and kits for the prognosis and treatment of prostate cancer.... Agent: University Of South Alabama
20130039906 - Pyrazolo[3,4-c]pyridine compounds and methods of use: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro,... Agent:
20130039911 - Compositions and methods for targeted immunomodulatory antibodies and fusion proteins: The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability... Agent:
20130039910 - Methods and compositions for modulating angiogenesis and pericyte composition: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may... Agent: Acceleron Pharma, Inc.
20130039912 - Robo1-fc fusion protein and use thereof for treating tumours: The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant Another aspect of the invention involves using a Robo1-Fc molecule as a... Agent: Sanofi
20130039913 - Heterodimeric antibody fc-containing proteins and methods for production thereof: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.... Agent: Genmab A/s
20130039917 - Diagnostic and therapeutic target: The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates... Agent: Avicenna Research Institute
20130039916 - Engineered anti-il-23p19 antibodies: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.... Agent: Merck Sharpe & Dohme Corp.
20130039914 - Novel human genes relating to respiratory diseases and obesity: This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.... Agent:
20130039919 - Novel plasminogen receptor, polypeptides and antibodies thereof: The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-RKT, or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin 1 and other plasminongen fragments... Agent:
20130039918 - Pharmaceutical composition using connective-tissue growth factor: This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound... Agent: Postech Academy-industry Foundation
20130039915 - Siglec 15 antibodies in treating bone loss-related disease: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell... Agent: Alethia Biotherapeutics Inc
20130039920 - Specific binding proteins and uses thereof: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR... Agent: Shanghai Cancer Institute
20130039921 - Treatment of inflammatory skin disease and psychiatric conditions: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment.... Agent: Xbiotech, Inc.
20130039924 - Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular... Agent:
20130039925 - Alternative pathway specific antibodies for treating arthritis: A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the... Agent:
20130039923 - Anti-human interleukin-20 antibodies: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods... Agent: Novo Nordisk A/s
20130039922 - Antibodies that inhibit metalloproteins: The present application relates to antibodies which recognize [2 (2-aminoethylcarbomoyl)-ethoxymethyl]-tris-[2-N-(3-imidazol-1-yl-propyl))-ethoxymethyl]methane, a hapten molecule which closely mimics the local structure and conformation of the reactive zinc site in matrix metalloproteinases. An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group... Agent: Yeda Research And Development Co. Ltd.
20130039927 - Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that... Agent: University Of Rochester
20130039926 - Human antibodies against rabies and uses thereof: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.... Agent: University Of Massachusetts
20130039928 - Compositions and methods for reversing corticosteroid resistance or treating respiratory infections: The present invention features methods for reversing corticosteroid resistance, as well as for the treatment of respiratory infections, particularly those associated with chronic obstructive pulmonary disease. In one embodiment, the method increases Nrf2 biological activity or expression.... Agent: The Johns Hopkins University
20130039929 - Method treating breast cancer: The present invention relates, in general, to breast cancer and, in particular, to methods of treating breast cancer comprising administering to a subject in need thereof an agent that modulates signal transduction regulated by β-arrestin (e.g., β-arrestin 1). The invention further relates to methods of identifying compounds suitable for use... Agent:
20130039930 - Biomarker for sensitivity to therapy with a notch inhibitor: Described herein are materials and methods for identifying subjects that would benefit from Notch-targeted therapy.... Agent:
20130039931 - Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof: The present application provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses... Agent:
20130039932 - Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent: Disclosed is a quickly soluble oral film dosage for masking a nasty taste, in particular, a quickly soluble oral film dosage comprising a stevioside based sweetener and a high potency sweetener in a ratio by weight (w/w) of 1:3 to 3:1, which may efficiently mask a bitter or nasty taste... Agent: Chabio & Diostech Co., Ltd.
20130039936 - Immunogenic pote peptides and methods of use: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services
20130039935 - Induction of tumor immunity by variants of folate binding protein: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such... Agent: The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
20130039933 - Sting (stimulator of interferon genes), a regulator of innate immune responses: Novel molecules termed STING which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. STING compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity.... Agent: University Of Miami
20130039934 - Treatment of ige-mediated disease: The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis,... Agent: Boston Medical Center Corporation
20130039937 - Peptide sequences and compositions: e
20130039938 - Highly efficient influenza matrix (m1) proteins: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.... Agent: Novavax, Inc.
20130039939 - Lipopeptide- and lipoprotein-conjugates and its use: Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines. In addition, said... Agent:
20130039940 - Homogenous vaccine composition comprising a conjugate of egf and p64k for the treatment of tumors: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity... Agent:
20130039941 - Vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5: The present invention pertains to the use of Haemophilus parasuis bacteria of serotype 5 expressing an iron-restriction protein visible on a Western-blot when reacted with serum of a convalescent animal which has recovered from an infection by Haemophilus parasuis bacteria of serotype 4, the said protein not being visible on... Agent: Intervet International B.v.
20130039942 - Compositions and methods for self-adjuvanting vaccines against microbes and tumors: The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immuno stimulator intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into... Agent:
20130039943 - Novel method: e
20130039944 - Anti-viral compounds: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.... Agent: Kineta, Inc.
20130039945 - Anti-viral compounds: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.... Agent: Kineta, Inc.
20130039946 - Vaccine comprising an attenuated pestivirus: Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Ems in addition to the inactivation of... Agent: Boehringer Ingelheim Vetmedica Gmbh
20130039947 - Novel immunogens and methods for discovery and screening thereof: The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a... Agent: Children's Medical Center Corporation
20130039948 - Inhibition of tcr signaling with peptide variants: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend... Agent: Signablok, Inc.
20130039949 - Immunomodulating compounds and related compositions and methods: Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.... Agent:
20130039952 - Calcipotriol monohydrate nanocrystals: Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions.... Agent: Leo Pharma A/s
20130039960 - Compositions for reduction of side effects: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticulate, non-nanoparticulate, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.... Agent:
20130039954 - Control of antibody responses to synthetic nanocarriers: Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods.... Agent: Selecta Biosciences, Inc.
20130039957 - Controlled release pharmaceutical compositions of brivaracetam: The present invention relates to controlled release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable derivatives thereof. Further disclosed is a controlled release pharmaceutical composition comprising a core and a coating surrounding the core, wherein the core comprises Brivaracetam or pharmaceutically acceptable derivative thereof and the coating comprises hydrophobic release... Agent: Lupin Limited
20130039953 - Method for treating a surface with a coating comprising a therapeutic agent and device with treated surface: A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the... Agent: Covalon Technologies
20130039959 - Method of inhibiting hiv and barrier-forming composition therefor: A method for blocking, neutralizing, or killing human immunodeficiency virus (HIV) beginning prior to or during a human encountering an HIV contaminated environment or item includes: identifying a contaminated environment or item that is known or expected to be contaminated with HIV; and administering an effective amount of a barrier-forming... Agent:
20130039958 - Method of vaccination: The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional... Agent: Dbv Technologies
20130039950 - Neti-pot packet mixture: A nasal rinse composition comprising about 54 to 90 wt. % of sodium chloride and about 10 to 46 wt. % of sodium bicarbonate, and a kit comprising a packet that contains the rinse composition and a nasal rinse dispenser.... Agent: Church & Dwight Co., Inc.
20130039955 - Orally ingested metabolic enhancer in oral thin film container: An orally ingestible energy-boosting device is provided for facilitating a temporary metabolic increase in a user. The device comprises a small container filled with an energy-enhancing substance. All or a portion of the small container is constructed of a water or saliva-soluble film that dissolves when placed in the mouth... Agent:
20130039951 - Process of preparing a stabilized and solubilized formulation of sirolimus derivatives: Provided is a process for preparing a solubilized and stabilized formulation of a sirolimus derivative, which comprises the steps of a dissolving a sirolimus derivative in a solvent, and bring a solution of the sirolimus derivative into contact with a water-soluble carrier to disperse the sirolimus derivative in the water-soluble... Agent: Dong-a Pharm. Co., Ltd.
20130039956 - Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns: The invention is directed to implants and medical devices having at least one layer which contains at least one nitrocarboxylic acid. These implants and medical devices shall be used for the prophylaxis and treatment of aggressive healing patterns. Furthermore, this invention relates to the use of nitrocarboxylic acids and their... Agent:
20130039963 - Composition comprising a superabsorbent polymer and a gemini surfactant: Wherein: R1 and R3 denote, independently of each other, an alkyl radical containing from 1 to 25 carbon atoms; R2 denotes a spacer formed from a linear or branched alkylene chain containing from 1 to 12 carbon atoms; X and Y denote, independently of each other, a group —(C2H4O)a—(C3H6O)bZ, in... Agent:
20130039962 - Encapsulates: The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene... Agent:
20130039961 - Personal care compositions comprising shaped abrasive particles: A personal care composition is disclosed comprising abrasive particles. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.... Agent:
20130039964 - Metal entrapped bioactive composites: The present invention provides composites comprising at least one bioactive agent entrapped within a matrix of at least one metal; wherein said composite controllably releases at least one of said bioactive agent and metal or ion thereof, processes for the preparation of composites of the invention, compositions and products comprising... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.
20130039965 - Coated granular material and method for producing coated granular material: A coated granular material of the present invention includes: a water-soluble granular substance; a coating layer applied to at least a surface of the water-soluble granular substance and containing a thermosetting resin A formed from a resin liquid having a molar ratio A of isocyanate groups to hydroxyl groups of... Agent: Central Glass Company, Limited
20130039966 - Bone semi-permeable device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC
20130039967 - Oral dosage forms: The invention relates to specific three layer dosage forms for oral administration of pharmaceutical active substances.... Agent: Novartis Ag
20130039968 - Materials and processes for producing antitoxic fabrics: The invention provides a novel method of generating fabrics with outstanding antitoxic properties. The antitoxic properties are imparted to the fabric by introducing an active agent such as an antimicrobial or antiviral agent to the fabric. The active agent may be introduced into the fabric at multiple stages of the... Agent: Triomed Innovations Corp.
20130039974 - Anti-muc1 antibodies for cancer diagnostics: The present invention is directed to antibodies binding to the MUC1 cytoplasmic domain and methods of using such antibodies to treat, diagnose, detect and monitor cancers that express the MUC1 antigen.... Agent:
20130039971 - Compositions and methods for inhibition of vegf: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.... Agent: Opko Ophthalmics, LLC
20130039972 - Compositions and methods of use of targeting peptides against placenta and adipose tissues: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents... Agent:
20130039975 - Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use: Unilamellar liposomes comprising PGE1 and/or PGE1-α-cyclodextrin combined with carnitine, in which there are hydrophilic polymers on the external surface of the liposomes are described.... Agent: Bioricerca Di Giovanni Brotzu & C. Snc
20130039969 - Method and composition for treating rhinitis: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.... Agent: Biolipox Ab
20130039977 - Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof: Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration... Agent: Busulipo Ab
20130039970 - Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics: Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an... Agent: Marina Biotech, Inc.
20130039976 - Sodium channel blocker for treatment of loss of superficial sensitivity: The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal.... Agent: Phytotox Limited
20130039973 - Viral immunogenic compositions: Disclosed herein are immunogenic compositions for producing immediate and sustained immunity to infectious viral and bacteriological pathogens. A univalent immunogenic composition is disclosed comprising an isolated antigen and a polynucleotide formulated into a nanoparticle or liposome. Furthermore, multivalent immunogenic compositions are disclosed comprising multiple univalent immunogenic compositions. Also disclosed, are... Agent:
20130039978 - Medicinal compositions and method for treatment of urinary tract infections: The invention describes medicinal compositions, comprising combination of essential oils, and method for treatment of cystitis and urinary tract infections by oral administration of such compositions.... Agent:
20130039980 - Time release capsule for beverage: This invention relates to time-release capsules administered in beverage preparations. The present invention may be used for administration of delayed-release flavor or color enhancement of the beverage preparation. It may also be used for the oral administration of pharmaceutical compounds, vitamins, or other active compounds, including herbal ingredients, to a... Agent:
20130039981 - Quick dissolving, long acting zinc therapeutic formulations: The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive polymers as a controlled release oral drug delivery system. The composition allows for increased residence time for enhanced prophylactic and therapeutic efficacy within the mouth and oral... Agent:
20130039982 - Low-dose tablets and preparation process: The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent... Agent: Ethypharm
20130039984 - Manufacture process for the preparation of an iron containing phosphate adsorbent: The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties.... Agent: Novartis Ag
20130039983 - Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects: The crystalline hemihydrate pseudopolymorph form H of ralfinamide methanesulfonate, or its R-enantiomer, is a useful intermediate for obtaining the crystalline anhydrous polymorph A free from the above impurities having genotoxic effect and/or residual solvents known as precursors thereof, and exhibits a physicochemical profile conferring significant advantages in the design and... Agent: Newron Pharmaceuticals S.p.a.
20130039985 - Method for aligning cells and applying homogenous strain throughout deformable engineered tissue constructs: A process creates a homogenous sheet of engineered tissue comprised of encapsulated cells and a deformable engineered tissue construct. In the embodiment consisting of a collagen construct with encapsulated cells capable of contracting the matrix, the collagen fibers and encapsulated cells are aligned during the process. An apparatus can deliver... Agent:
20130039986 - Silk-based ionomeric compositions: Disclosed herein are pH-dependent silk fibroin-based ionomeric compositions and colloids, and methods of making the same. The state of the silk fibroin ionomeric compositions is reversible and can transform from a gel-like colloid to a more fluid-like solution, or vice versa, upon an environmental stimulus, e.g., pH. Thus, the silk-based... Agent: Trustees Of Tufts College
20130039988 - Active pellet excluding chemical additives: Disclosed herein is an active pellet. The active pellet includes a body and interspaces. The body includes an active ingredient ranging from 50 to 100 wt %, free of chemical additives.... Agent: Bio-trend Pharmaceutical Co.,ltd
20130039987 - Method for increasing the solubility of a transcriptase inhibitor composition: The invention provides a method for increasing the solubility of nevirapine, including the steps of rendering nevirapine in a gaseous phase; and rendering the gaseous phase in a relatively more soluble solid particulate form. The invention further provides for a crystalline Form-VI (36) of nevirapine having an X-ray diffraction pattern... Agent: North-west University
20130039989 - Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to... Agent:
20130039990 - Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering: The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same.... Agent: University Of Maryland, Baltimore
20130039991 - Elimination of n-glycolylneuraminic acid from animal products for human use: The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans.... Agent: The Regents Of The University Of California
20130039992 - Honey-based gel composition: A honey based composition is described. The composition includes a mixture of honey, a short chain fatty alcohol and a fatty ester or wax. The composition has applications for use in wound dressings and in one embodiment may be a gel. The composition has a higher than expected storage stability,... Agent: Comvita New Zealand Limited
20130039993 - Argon-based inhalable gaseous medicament against peripheral organ deficiencies or failures: The invention relates to a gaseous composition containing an effective amount of argon gas for use, by inhalation, in preventing or treating a deficiency or failure of at least one peripheral organ in a patient. Preferably, it contains between 15 and 80% by volume of argon, and oxygen, preferably at... Agent: L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude
20130039994 - Low dose colonic cleansing system: A method of colonic cleansing that includes administering orally a first dose and a second dose of a liquid osmotic colonic evacuant composition. The second dose includes an amount of the liquid osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose.... Agent:
20130039996 - Potentiation of cancer chemotherapy by 7-(2, 5- dihydro- 4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine: An improved method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions useful for the method and a process for preparing said compositions.... Agent: Eli Lilly And Company
20130039997 - Method for the eradication of pathogens including s. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells: A method for killing or substantially eradicating a pathogen in the upper respiratory tract of a mammal is disclosed. The method comprises generating molecular iodine (I2) in situ using an oxidant-reductant reaction with a minimum concentration of at least about 25 ppm of I2 and I2 comprises at least 40%... Agent: Iogen LLC
20130039998 - Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder: The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present... Agent: Massachusetts Institute Of Technology
20130039999 - Use of clays for treating coeliac disease: The invention relates to the use of a clay for the preparation of a medicament for treating coeliac disease. Preferably, the clay used is of smectite type.... Agent: Ipsen Pharma S.a.s.
20130040000 - Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas: Disclosed are methods of reducing the risk of occurrence of pulmonary edema associated with a medical treatment comprising inhalation of nitric oxide gas.... Agent: Ino Therapeutics LLC
20130040001 - Method of processing animal skin: The present invention provides a method of processing animal skin, comprising the steps of: 1) providing dry animal skin containing 7-38 wt % water; 2) rehydrating and softening the said dry animal skin, and obtaining softened wet skin; 3) mixing the said softened wet skin with water, and grinding the... Agent:
20130040002 - Anti-oxidant herbal composition: The present disclosure relates to a novel Anti-Oxidant Herbal composition comprising Termanalia arjuna extract, Camellia sinensis extract, and Trikatu extract in specific weight percentages and optionally at least one carrier. The present disclosure further relates to use of the composition for treatment and/or prevention of hyperlipidemia and/or Ischemic heart disease.... Agent:
20130040003 - Natural - topical analgesic and anti-inflammatory composition: This invention replaces the practice of utilizing synthesized salicin compounds for use as anti-inflammatory components in topical pain relief compositions through the use of naturally occurring salicin in the form of salix alba (white willow bark) botanicals. This invention is a compound of naturally occurring botanicals identified in the Natural... Agent:
20130040004 - Plant extract for treating diabetes and process for making same: The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of Hedychium coronarium Koenig, which has the efficacies of lowering blood glucose, increasing insulin levels, reducing insulin resistance and treating and/or... Agent: Development Center For Biotechnology
20130040005 - Antihypertensive agents: The present invention relates to an antihypertensive agent including a boysenberry seed extract as an active ingredient. According to the invention, there can be provided an effective and highly safe antihypertensive agent having antihypertensive effect so that the agent can contribute to the prevention and amelioration of hypertension and having... Agent: Bourbon Corporation
20130040006 - Extracts of eleutherococcus spp., preparation method thereof and use of the same: The present invention relates to extracts of Eleutherococcus spp. and the preparation process thereof. The present invention also relates to the use of the Eleutherococcus spp. extracts of the present invention for the treatment or prevention of at least one condition of metabolic syndrome.... Agent: Food Industry Research And Development Institute
20130040007 - Antituberculosis composition of byttneria species: Active fractions exhibiting anti-tuberculous activity from the plant Byttneria herbecea (family—Sterculiaceae) are described. Methanol extracts of the aerial part of Byttneria herbecea exhibited activity against MtbGS in primary screening of biosynthetic assay. Subsequent fractionation was carried out in organic solvents. Out of all these, two fractions (fraction D and K)... Agent: Council Of Scientific & Industrial Research02/07/2013 > 129 patent applications in 84 patent subcategories. patent applications/inventions, industry category
20130034492 - Class i anti-cea antibodies and uses thereof: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR... Agent: Immunomedics, Inc.
20130034493 - Methods and compositions for modulation of olfml3 mediated angiogenesis: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.... Agent:
20130034494 - Radiolabeled prostate specific membrane antigen inhibitors: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated... Agent: Molecular Insight Pharmaceuticals
20130034495 - Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol: Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.... Agent:
20130034496 - Positron emission tomography tracer: The present invention relates to positron emission tomography tracers and methods of using these tracers.... Agent: University Of Iowa Research Foundation
20130034497 - Iodine-labeled homoglutamic acid and glutamic acid derivatives: This invention relates to derivatives of Iodine-labeled homoglutamic acids and glutamic acids and their analogues suitable for labeling or already labeled by Iodine, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging or... Agent: Piramal Imaging Sa
20130034498 - Optical microlabels: shapes and reflectors: Labels and methods of producing labels for use in clinical, analytical and pharmaceutical development assays are provided. Labels may comprise shape-encoded particles which may be coupled to ligands such as DNA, RNA and antibodies, where different shapes are used to identify which ligand(s) are present. Labels may also comprise reflectors,... Agent:
20130034500 - Cationic steroid antimicrobial compositions and methods of use: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV)... Agent:
20130034501 - Diarylhydantoin compounds: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone lefiactory prostate cancer.... Agent: The Regents Of The University Of California
20130034499 - Sgii as a prognostic marker in conditions which require critical care: The present invention relates to methods for determining the prognosis of a condition which requires critical care, said methods comprising determining the level of SgII, or fragments thereof in a subject. The methods of the invention can also be used to determine whether an individual is suffering from a condition... Agent: Universitetet I Oslo
20130034502 - Color changing cosmetic: The present invention is a substance that allows users to monitor temperature changes and appearance cosmetically on the human body by a change in color of the applied substance. It is intended for direct application to the skin and hair. The range of colors can be adjusted depending on the... Agent:
20130034503 - Preventing or reducing drug abuse and overdose events: A method and compositions for treating a patient that prevent or reduce drug abuse and overdose events.... Agent:
20130034504 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity: Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.... Agent: Chiesi Farmaceutici S.p.a.
20130034505 - Cassia derivatives: This invention related to a cationically and hydrophilically modified polygalactomannan having repeating units with an average D-mannosyl to D-galactosyl residue ratio of at least 5 to 1 and to compositions containing the same. A portion of the hydrogen atoms of hydroxyl groups situated on the mannosyl and galactosyl residues of... Agent: Lubrizol Advanced Materials, Inc.
20130034506 - Water-soluble surfactant compositions having improved taste: Treated surfactant composition containing a water-soluble surfactant and exhibiting improved taste, said composition comprising: a water-soluble surfactant selected from alkyl phosphate surfactants, alkyl phosphate ethoxylated surfactants, betaine surfactants, betaine ethoxylated surfactants, amine oxide surfactants, and mixtures thereof and water; wherein the composition further comprises: less than about 4%, by weight... Agent:
20130034507 - Chlorine dioxide treatment for biological tissue: Methods, compositions, devices, and systems for administration to a biological tissue of a composition comprising a chlorine dioxide source are provided.... Agent: Basf Corporation
20130034508 - Process for surfactant taste and/or odor improvement: Processes for improving the taste of water-soluble surfactants using liquid-liquid solvent extraction, said process comprising the steps of: providing a water-soluble surfactant composition in need of treatment wherein said water-soluble surfactant composition comprises a water-soluble surfactant and one or more undesirable non-polar materials; contacting said water-soluble surfactant composition with an... Agent:
20130034509 - Cosmetic treatment method involving a compound capable of condensing in situ: The present invention relates to a method for the cosmetic treatment of the skin involving a compound, or set of compounds, capable of condensing in situ.... Agent: L'oreal
20130034510 - Melanin modification compositions and methods of use: A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well... Agent: Skinmedica, Inc.
20130034511 - Novel compound: The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils.... Agent:
20130034512 - Easily appliable, storage stable, radiation-curable, pigmented, artificial nail gel coatings: A composition, method, and use of a UV curable, thixotropic, radiation curable, low viscosity gel is described. The composition is comprised of thixotropic additive(s) and in some cases dispersants for additional dispersion stability. The thixotropic pigmented gel has prolonged shelf life and long time storage at ambient conditions. It also... Agent: Mycone Dental Supply Co., Inc.
20130034513 - Use of a cosmetic composition comprising at least one film-forming elastomeric polymer for treating human perspiration: The present invention relates to the use of a cosmetic composition comprising, in a cosmetically acceptable medium, one or more nonionic, anionic, amphoteric or cationic film-forming elastomeric polymers, capable of giving, on drying of the said elastomeric polymer(s), at room temperature and at a relative humidity of 55%, a material... Agent:
20130034515 - Hair care compositions: This document provides methods and materials related to hair care. For example, hair care compositions containing one or more quaternized polysiloxanes, one or more zwitterionic surfactants, one or more anionic surfactants, one or more botanical compounds, one or more amino acids, one or more vitamins, or any combination thereof as... Agent: Melaleuca, Inc.
20130034516 - Use of the modified polysaccharides for heparin neutralization: The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing... Agent: Uniwersytet Jagiellonski
20130034517 - Targeted drug phosphorylcholine polymer conjugates: The present invention provides random copolymers containing phosphorylcholine and one or more functional agents, and methods of preparing such random copolymers.... Agent: Oligasis
20130034520 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Bristol-myers Squibb Company
20130034518 - Interleukin-12 p40 variants with improved stability: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.... Agent: Merck Patent Gmbh
20130034519 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent:
20130034521 - 1'-substituted carba-nucleoside analogs for antiviral treatment: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.... Agent: Gilead Sciences, Inc.
20130034522 - Therapies for treating hepatitis c virus infection: A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to... Agent: Vertex Pharmaceuticals Incorporated
20130034523 - Use of sdf-1 to mitigate scar formation: The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the... Agent: The Cleveland Clinic Foundation
20130034527 - Mitochondrial enhancement of cells: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells... Agent: Searete LLC
20130034525 - Beta iselets-like cells derived from whole bone marrow: The invention provides for methods of producing pancreatic precursor cells and insulin-producing cells from bone marrow. In various embodiments, bone marrow derived stem cells are differentiated into pancreatic precursor cells and insulin-producing cells. In various embodiments, bone marrow derived stem cells are artificially induced to express VEGF and/or PDX-1. These... Agent: Cedars-sinai Medical Center
20130034524 - Non-enzymatic method for harvesting adipose-derived stromal cells and adipose-derived stem cells from fat and lipo-aspirate: The present disclosure relates generally to processes, devices and systems for separating and concentrating stem and stromal cells from adipose tissue using a combination of mechanical disruption and filtration-centrifugation to obtain a highly enriched population of stem cells.... Agent:
20130034528 - New methods for isolating tr1 cells: The present invention relates to methods for isolating Tr1 cells, resting Tr1 cells and/or activated Tr1 cells, to methods for enriching or depleting a cell population in Tr1 cells, resting Tr1 cells and/or activated Tr1 cells and to methods and kits for treating chronic inflammatory diseases, autoimmune diseases, allergic diseases,... Agent: Txcell
20130034530 - Dietary supplement cognitive support system: The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan,... Agent:
20130034532 - Nanozymes, methods of making nanozymes, and methods of using nanozymes: Embodiments of the present disclosure provides for nanozymes, methods of making nanozymes, methods of using nanozymes, and the like.... Agent:
20130034529 - Natural compositions and methods of promoting wound healing: Compositions comprising honey, myrhh, and Nigella Sativa seeds are described. The honey:myrrh:N. sativa seed ratio can be 100:0.5-50:0.1-10, based on weight. The compositions can also comprise one or more pharmaceutically acceptable diluents and/or excipients. Also described herein are methods for treating a wound comprising administering to the wound an effective... Agent:
20130034531 - Use of proteases for gluten intolerance: The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also... Agent:
20130034533 - High molecular weight derivatives of vitamin k-dependent polypeptides: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.... Agent: Regents Of The University Of Minnesota
20130034534 - Method for treatment of patients with cystic fibrosis: A method for treatment of patients with cystic fibrosis by providing an inhalable aerosol comprising a mucolytic compound (dornase alpha) administered into a patient's lungs according to a specific treatment protocol setting comprising a mucolytic drug containing aerosol having particles with a predetermined mass medial aerodynamic diameter (MMAD) delivered predominantly... Agent:
20130034535 - Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics: Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7... Agent: Pivotal Therapeutics Inc.
20130034536 - Bile acid recycling inhibitors for treatment of pancreatitis: Provided herein are methods and compositions comprising bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis.... Agent: Lumena Pharmaceuticals, Inc.
20130034537 - Simultaneous co-treatment of physical and mental symptoms related to severe mental disorders by a specially fermented soy formulation (fsww08): A method of treating severe mental diseases and related disorders or conditions includes administering to a patient in need thereof an effective amount of a composition including isoflavones and Bowman Birk Inhibitory Factor (BBIF). Preferably, the composition is a fermented soy composition. Preferably, one first diagnoses a patient with a... Agent:
20130034542 - Cold treatment: A use of a composition including lactoferrin and/or immunoglobulin for minimizing the severity of one or more symptoms associated with common cold and/or influenza.... Agent: Probiotec Limited
20130034540 - Immune gene signatures in cancer: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.... Agent: H. Lee Moffitt Cancer Center And Research Institute, Inc.
20130034543 - Modulating xrn1: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.... Agent: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear
20130034541 - Pharmaceutical compositions: A composition including lactoferrin and immunoglobulin, wherein the composition does not substantially include one or more of the following proteins: lactoperoxidase, lactoglobulin, albumin.... Agent: Probiotec Limited
20130034538 - Reverse hexagonal mesophases (hii) and uses thereof: Reverse hexagonal mesophase (HII) liquid crystals are provided and relating therapeutic and non-therapeutic applications are demonstrated.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.
20130034539 - Sr-bi as a predictor of human female infertility and responsiveness to treatment: Methods of diagnosis and treatment of diseases and disorders related to de novo synthesis of cholesterol, based on allelic variants of the scavenger receptor class B type I receptor, and kits for use therein.... Agent: The Johns Hopkins University
20130034546 - Analyzing copy number variation in the detection of cancer: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical... Agent: Verinata Health, Inc.
20130034549 - Combination therapy for treating breast cancer: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.... Agent:
20130034544 - Methods for treating, diagnosing, and monitoring lupus: Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1,... Agent: Genentech, Inc.
20130034547 - Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns: A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight... Agent:
20130034550 - Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier: A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.... Agent: Allergan, Inc
20130034545 - Treatment of traumatic brain injury using antibodies to lysophosphatidic acid: Methods are provided for treating traumatic brain injury (TBI) using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies. In particular, the TBI may be blast-induced TBI (bTBI) such as commonly occurs in battlefield injuries. The treatment may include functional locomotor... Agent:
20130034548 - Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an... Agent: Merrimack Pharmaceuticals, Inc.
20130034553 - Fusion polypeptides capable of activating receptors: A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a... Agent: Regeneron Pharmceuticals, Inc.
20130034552 - Temperature sensitive conjugate compositions, and uses related thereto: This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the... Agent: Emory University
20130034551 - Wnt antagonists and methods of treatment and screening: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and... Agent: Oncomed Pharmaceuticals, Inc.
20130034554 - Antibodies to il-6 and use thereof: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise... Agent: Alder Biopharmaceuticals, Inc.
20130034555 - Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases: A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2... Agent: The Regents Of The University Of California
20130034557 - Cancer-related glycopeptide epitopes, antibodies and methods of use: Cancer-associated O-glycopeptide combination epitopes derived from the VNTR of MUC1 are disclosed. Autoantibodies present in human sera target the combination epitopes and are reduced or absent in cancer patients. The epitopes are useful as therapeutic and immunoprophylactic cancer vaccines. Monoclonal antibodies directed against the epitopes are also useful as immunotherapeutics... Agent: Ezose Sciences, Inc.
20130034556 - Free hexasaccharide isolated from several campylobacter species: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound,... Agent: The Governors Of The University Of Alberta
20130034558 - Epidermal growth factor receptor variant: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion... Agent: Shanghai Cancer Institute
20130034561 - Isolated mammalian monocyte cell genes; related reagents: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.... Agent: Merck Sharp & Dohme Corp.
20130034560 - Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and... Agent:
20130034559 - Targeted binding agents against b7-h1: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed... Agent: Medlmmune Limited
20130034562 - Selective androgen receptor modulators for treating diabetes: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer... Agent:
20130034563 - Use for production of therapeutic agent or prophylactic agent for osteoarthritis: Methods for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or classified as grade 1 to 3 according to the Outerbridge classification of osteoarthritis, include administering... Agent: Axis Inc.
20130034564 - Anti-rsv g protein antibodies: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.... Agent:
20130034565 - Molecules and methods of using same for treating erbb/erbb ligands associated diseases: A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount... Agent: Yeda Research And Development Co., Ltd.
20130034566 - Anti-cdh3 antibodies and uses thereof: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present... Agent: Onco Therapy Science, Inc.
20130034569 - Il-18 receptor antigen binding proteins: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.... Agent:
20130034570 - Methods and compositions for modulating prostasin: The invention provides methods and compositions related to modulating prostasin.... Agent: Genentech, Inc.
20130034568 - Methods of treating or preventing periodontitis and diseases associated with periodontitis: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.... Agent:
20130034567 - Protein modulators: The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment... Agent: Novartis Ag
20130034571 - Methods for inducing in vivo tolerance: The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue.... Agent: The Washington University
20130034572 - Compositions and methods for brain delivery of analgesic peptides: The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also... Agent:
20130034575 - Method for identification, isolation and production of antigens to a specific pathogen: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized... Agent: Intercell Ag
20130034574 - Modified melk peptides and vaccines containing the same: Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context... Agent: Oncotherapy Science, Inc.
20130034573 - Vaccine compositions: The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions. The present disclosure further relates to methods of reducing abnormal cell growth using the composistions described herein.... Agent: Celldex Therapeutics, Inc.
20130034576 - Novel adenovirus isolated from titi monkeys: Provided is a Titi Monkey Adenovirus (TMAdV) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-TMAdV antibodies, vaccines, compositions, methods of detecting TMAdV, methods for assaying for anti-TMAdV compounds, and methods for treating or preventing a TMAdV infection.... Agent: The Regents Of The University Of California
20130034577 - Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an... Agent: Auburn University
20130034578 - Recombinant multimeric influenza proteins: The invention relates to immunogenic compositions comprising recombinant multimeric influenza proteins or parts thereof fused to a streptavidin affinity tag, preferably recombinant trimeric influenza virus hemagglutinin and/or recombinant tetrameric influenza virus neuraminidase, or vectors comprising nucleic acid sequences encoding such influenza proteins. The inventions further relate to methods for the... Agent:
20130034579 - Immunogenic compositions and related methods: This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing... Agent:
20130034580 - Novel formulations which stabilize and inhibit precipitation of immunogenic compositions: The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the... Agent: Wyeth LLC
20130034584 - Agent for use in the topical or local treatment of cervical dysplasias: The invention relates to an agent for treating cervical dysplasias, comprising a recombinant, genetically modified E1-deleted adenovirus replication defective in non-HPV infected cells, which is suitable for local external application in the region of the portio and the cervix uteri.... Agent: Charite - Universitaetsmedizin Berlin
20130034583 - Compositions, methods and uses for expression of enterobacterium-associated peptides: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or... Agent: Inviragen, Inc.
20130034581 - Genetically engineered swine influenza virus and uses thereof: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1... Agent:
20130034582 - Reverse genetics methods for virus rescue: A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.... Agent: Novartis Ag
20130034585 - Bovine herpes virus vaccine with multiple mutations: A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5Δ30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g.,... Agent:
20130034586 - Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response: The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a... Agent: New York University
20130034587 - Methods for treatment of incontinence associated with sexual activity: The invention provides compositions and methods for treating incontinence associated with sexual activity.... Agent: Allergan, Inc.
20130034588 - Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof: Infection by Chlamydia pneumoniae has been identified as a risk factor associated with the pathogenesis of certain chronic intraocular disorders, for example, age-related macular degeneration. The invention provides methods of identifying individuals at risk of developing chronic intraocular disorders, and methods of delaying and/or preventing the onset of such chronic... Agent: Massachusetts Eye And Ear Infirmary
20130034590 - Delivery of hydrophilic drugs: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention.... Agent:
20130034591 - Novel compounds and compositions for targeting cancer stem cells: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of... Agent: Boston Biomedical, Inc.
20130034589 - Ph-sensitive nanoparticles for oral insulin delivery: The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The present invention also includes a method for preparation of pH-sensitive nanoparticles, in particular, a multiple emulsions solvent evaporation method. The pH-sensitive nanoparticles of the present invention show good... Agent: Nano And Advanced Materials Institute Limited
20130034592 - Hydrogel: A hydrogel composed of a polyanionic polysaccharide derivative having a hydrophobic group introduced by covalent bonding and a salt solution with a salt concentration of 50 mM or more and 200 mM or less, the hydrogel having an aggregate structure with an average particle diameter of 100 to 2000 nm... Agent: Teijin Limited
20130034593 - Method for making medical devices having antimicrobial coatings thereon: The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by... Agent: Novartis Ag
20130034594 - Fibers containing ferrates and methods: A fiber containing ferrate, which comprises (1) one or more ferrate compounds, wherein the ferrate compound is selected from a group consisting of a metal ferrate(V) compound, metal ferrate(VI) compound, and a mixture thereof; and (2) one or more nonaqueous polymers. Also, methods are disclosed that make and/or use the... Agent: Battelle Memorial Institute
20130034595 - Local administration of gallium compositions to treat pain: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together... Agent:
20130034596 - Use of synthetic polysulphated oligosaccharides as cleaning agents for a wound: The present invention relates to the use of at least one compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and to the salts and complexes thereof as cleaning agents for a wound. The invention can be used in particular for preparing bandages intended for cleaning... Agent: Laboratoires Urgo
20130034598 - Inhibitors of akt/pkb with anti-tumor activity: The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an... Agent: University Of South Florida
20130034597 - Orally bioavailable peptide drug compositions and methods thereof: The present invention provides orally bioavailable peptide drug compositions including a cyclic peptide and an orally compatible absorption enhancer, as well as methods for providing increased oral bioavailability of peptide drugs.... Agent: Aegis Therapeutics LLC
20130034599 - Synthetic nanostructures including nucleic acids and/or other entities: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as... Agent: Northwestern University
20130034601 - Method for increasing lactose tolerance in mammals exhibiting lactose intolerance: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day... Agent: Ritter Pharmaceuticals, Inc.
20130034600 - Peptide pharmaceutical of oral delivery: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise... Agent: Unigene Laboratories Inc.
20130034602 - Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery: The invention relates to an enteric-coated capsule containing cationic nanoparticles for oral insulin delivery, in particular to a type of cationic nanoparticle including a polycationic and mucoadhesive polymer and a biodegradable polymer, wherein each of the nanoparticles has positive surface charge and enhanced permeability for paracellular insulin delivery; the enteric-coated... Agent: Nano And Advanced Materials Institute Limited
20130034603 - Process for preparing pharmaceutical compositions of fingolimod: The present invention provides a process for preparing a pharmaceutical composition of fingolimod comprising: (i) obtaining a intimate admixture comprising fingolimod or a pharmaceutically acceptable salt thereof, and at least one surfactant (wetting agent), e.g., an intimate admixture of the fingolimod and the at least one surfactant, and (ii) optionally... Agent:
20130034604 - Extended release formulations of desvenlafaxine base: An extended release pharmaceutical composition comprising micronized desvenlafaxine base, at least one pH modifier and at least one release controlling agent and its process for preparation. An extended release monolithic tablet is also provided. Further extended release tablets comprising micronized desvenlafaxine base; at least one pH modifier; at least one... Agent: Alembic Pharmaceuticals Limited
20130034605 - Extended release pharmaceutical compositions containing paliperidone: An extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same. The present invention particularly relates to an extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients wherein the... Agent: Micro Labs Limited
20130034606 - Immediate release tablet formulations: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated... Agent: Bristol-myers Squibb Company
20130034607 - Tablet: The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge.... Agent: Mitsubishi Tanabe Pharma Corporation
20130034608 - Long circulating nanoparticles for sustained release of therapeutic agents: The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.... Agent:
20130034609 - Smart polymers functionalized hollow silica vesicles: The present invention provides a porous hollow silica micro- or nanoparticle with a polymer grafted thereon, wherein the polymer is selected from poly(methacrylic acid) and copolymers thereof. The polymer may be covalently linked to the silica particle via a bridging group. Provided is also a method of covalently coupling a... Agent: Agency For Science, Technology And Research
20130034610 - Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells: Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule,... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130034611 - Sustained preparation of factor ix: The present invention provides a pharmaceutical preparation in powder-like form, comprising a therapeutically effective amount of a human Factor IX (hFIX) encapsulated by a lipophilic biodegradable polymer or copolymer to form a microsphere, whereby the pharmaceutical preparation provides a sustained release of hFIX and a prolonged biological activity.... Agent: Animal Technology Institute Taiwan
20130034612 - Dermatological compositions comprising avermectin nanocapsules: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.... Agent: Galderma S.a.
20130034613 - Formulations of phosphites: The invention relates to a composition comprising a phosphite compound, a lignin compound and a pesticide adjuvant. The invention further relates to the use of the composition of the invention, and to methods of reducing the phytotoxicity of a composition comprising a phosphite compound and an adjuvant. The invention also... Agent: Ceradis B.v.
20130034614 - Method of treating citrus plants to reduce bacterial infections: A method of treating a citrus plant is provided to reduce the incidence of one or more insect-vectored bacterial infections such as citrus greening. The method comprises the step of applying a treatment composition one or more times to the plant, wherein the treatment composition comprises an effective amount of... Agent:
20130034615 - Lotion for cleaning human anorectal area: A cleansing lotion composition of zinc derivatives, aloe vera, lanolin and a mixture of water-based emulsifying agents for reducing itchiness, promoting healing and reducing inflammation around the anorectal area of a human subject is disclosed. The subject conveniently spreads a suitable amount of the cleansing lotion placed on toilet paper... Agent:
20130034616 - Compounds useful as inhibitors of atr kinase: c
20130034617 - Gallium compositions for the treatment of liver cancer and methods of use: Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as many cancers metastatic to the liver, can be treated. The treatments comprise the administration of pharmaceutically acceptable gallium... Agent:
20130034618 - Compositions for treating the integument: Fungal infections and other disease conditions of the integument can be effectively treated with compositions containing ozonizable oils and antimicrobials, when used in conjunction with solutions containing sodium chlorite. The compositions are particularly useful for treatment of resistant fungal infections.... Agent:
20130034620 - Antibacterial synthetic fiber and manufacturing method thereof: Disclosed are an antibacterial synthetic fiber, and a method for manufacturing the same, characterized in that one or more antibacterial plant extracts are mixed with a fiber-formable polymer and the mixture is melt spun at 200˜300° C. The antibacterial synthetic fiber exhibits excellent and persistent antibacterial activity. In addition, the... Agent:Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20130613:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 2.97552 seconds